

09/405,046

Trying 3106016892...Open

Welcome to STN International! Enter x:x  
LOGINID:sssptal208dxj  
PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files  
NEWS 3 Feb 06 Engineering Information Encompass files have new names  
NEWS 4 Feb 16 TOXLINE no longer being updated  
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure  
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA

NEWS EXPRESS April 18 CURRENT WINDOWS VERSION IS V6.0,  
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),  
AND CURRENT DISCOVER FILE IS DATED 04/06

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:53:53 ON 04 MAY 2001

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.15	0.15

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 15:53:58 ON 04 MAY 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 3 MAY 2001 HIGHEST RN 334615-05-3

DICTIONARY FILE UPDATES: 3 MAY 2001 HIGHEST RN 334615-05-3

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

09/405,046

Structure search limits have been increased. See HELP SLIMIT  
for details.

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\STNEXP4\QUERIES\405046elect.str

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> d

L2 HAS NO ANSWERS

L1 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

=> s 12

SAMPLE SEARCH INITIATED 15:54:29 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 104 TO ITERATE

100.0% PROCESSED 104 ITERATIONS

17 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 1469 TO 2691

PROJECTED ANSWERS: 93 TO 587

L3 17 SEA SSS SAM L1

=> s 12 full

FULL SEARCH INITIATED 15:54:38 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1967 TO ITERATE

100.0% PROCESSED 1967 ITERATIONS

434 ANSWERS

SEARCH TIME: 00.00.01

L4 434 SEA SSS FUL L1

=> e gadolinium/cn

E1 1 GADOLINITE-(Y)/CN

E2 1 GADOLINITE-(Y) (BE2FESI2(Y0.5-1CE0-0.5ND0-0.5)2O10)/CN

E3 1 --> GADOLINIUM/CN

E4 1 GADOLINIUM ((ETHYLENEDINITRILO)TETRAACETATO)CADMATE/CN

E5 1 GADOLINIUM

((ETHYLENEDINITRILO)TETRAACETATO)COBALTATE(II)/CN

E6 1 GADOLINIUM ((ETHYLENEDINITRILO)TETRAACETATO)ZINCATE/CN

09/405,046

E7 1 GADOLINIUM (DIPHOSPHATE) HYDROXIDE (GD5(P2O7)3(OH)3)/CN  
E8 1 GADOLINIUM +59 ION/CN  
E9 1 GADOLINIUM .ALPHA.-METHYLACRYLATE/CN  
E10 1 GADOLINIUM 0-0.6, LANTHANUM 99-100 (ATOMIC)/CN  
E11 1 GADOLINIUM 0-0.9, IRON 15, NICKEL 84-85/CN  
E12 1 GADOLINIUM 0-0.94, TERBIUM 99.1-100 (ATOMIC)/CN

=> s e3

L5 1 GADOLINIUM/CN

=> fil .search

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

137.67

137.82

FILE 'MEDLINE' ENTERED AT 15:55:00 ON 04 MAY 2001

FILE 'CAPLUS' ENTERED AT 15:55:00 ON 04 MAY 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:55:00 ON 04 MAY 2001

COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 15:55:00 ON 04 MAY 2001

CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:55:00 ON 04 MAY 2001

COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

=> s l4 and l5

L6 144 L4 AND L5

=> s l6 and (peptide? or polypeptide?)

L7 42 L6 AND (PEPTIDE? OR POLYPEPTIDE?)

=> dup rem l7

PROCESSING COMPLETED FOR L7

L8 40 DUP REM L7 (2 DUPLICATES REMOVED)

=> d ibib ab hitstr l-

YOU HAVE REQUESTED DATA FROM 40 ANSWERS - CONTINUE? Y/(N):y

09/405,046

L8 ANSWER 1 OF 40 CAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 2001:101192 CAPLUS  
 DOCUMENT NUMBER: 134:177353  
 TITLE: Binding moieties for fibrin  
 INVENTOR(S): Wescott, Charles R.; Nair, Shrikumar A.; Kolodziej,  
 Andrew; Beltzer, James P.  
 PATENT ASSIGNEE(S): Dyax Corp., USA; Epix Medical, Inc.  
 SOURCE: PCT Int. Appl., 114 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009188	A1	20010208	WO 2000-US20612	20000728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-146425 P 19990729  
 AB The present invention provides binding moieties for fibrin, which have a variety of uses wherever detecting, isolating or localizing fibrin, and particularly fibrin as opposed to fibrinogen, is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding fibrin and recognizing the form of polymd. fibrin found in thrombi. Such polypeptides and disclosed derivs. are useful, e.g., as imaging agents for thrombi. Preferred embodiments useful as magnetic resonance imaging (MRI) contrast agents useful for detecting a thrombus in vivo are also disclosed.  
 IT 7440-54-2, Gadolinium, biological studies 60239-18-1, DOTA  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (imaging agent comprising fibrin-binding polypeptides for screening thrombolytic agents and for diagnosing and treating

L8 ANSWER 2 OF 40 CAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 2001:101006 CAPLUS  
 DOCUMENT NUMBER: 134:168313  
 TITLE: Targeting multimeric imaging agents through multilocus  
 INVENTOR(S): binding  
 Lauffer, Randall B.; Mcmurry, Thomas J.; Dumas, Stephane; Kolodziej, Andrew; Amedio, John; Caravan,  
 Peter; Zhang, Zhao; Nair, Shrikumar  
 PATENT ASSIGNEE(S): Epix Medical, Inc., USA  
 SOURCE: PCT Int. Appl., 107 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001008712	A2	20010208	WO 2000-US20536	20000728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-146414 P 19990729  
 US 1999-163650 P 19991104  
 AB The present invention relates to contrast agents for diagnostic imaging. In particular, this invention relates to novel multimeric compds. which exhibit improved relaxivity properties upon binding to endogenous proteins or other physiol. relevant sites. The compds. consist of: a) two or more Image Enhancing Moieties (IEMs) (or signal-generating moiety) comprising multiple subunits; b) two or more Target Binding Moieties (TBM), providing for in vivo localization and multimer rigidification; c) a scaffold framework for attachment of the above moieties; and d) optional linkers for attachment of the IEMs to scaffold. This invention also relates to pharmaceutical compns. comprising these compds. and to methods of using the compds. and compns. for contrast enhancement of diagnostic

L8 ANSWER 1 OF 40 CAPLUS COPYRIGHT 2001 ACS (Continued)  
 thrombus-assocd. diseases)  
 RN 7440-54-2 CAPLUS  
 CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

RN 60239-18-1 CAPLUS  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6  
 REFERENCE(S):  
 (1) Athena Neurosciences Inc; WO 9601644 A1 1996 CAPLUS  
 (2) Genentech Inc; WO 9845331 A2 1998 CAPLUS  
 (3) Primalco Ltd; WO 9714804 A1 1997 CAPLUS  
 (4) Schering Biotech Corporation; EP 0329363 A1 1989  
 CAPLUS  
 (5) The Regents Of The University Of Michigan; WO 9636361 A1 1996 CAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 40 CAPLUS COPYRIGHT 2001 ACS (Continued)  
 imaging.  
 IT 7440-54-2DTP, Gadolinium, complexes with DTPA derivs.  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (targeting multimeric imaging agents through multilocus binding)  
 RN 7440-54-2 CAPLUS  
 CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

IT 60239-18-1D, DOTA, gadolinium-complexed derivs. and conjugates  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (targeting multimeric imaging agents through multilocus binding)  
 RN 60239-18-1 CAPLUS  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



09/405,046

L8 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 1  
 ACCESSION NUMBER: 2000:661180 CAPLUS  
 DOCUMENT NUMBER: 133:249059  
 TITLE: Radionuclide conjugates with DOTA-biotin derivatives  
 INVENTOR(S): for diagnosis and therapy  
 Serengulam Griffiths, Gary L.; Hansen, Hans; Govindan, V.  
 PATENT ASSIGNEE(S): Immunomedics, Inc., USA  
 SOURCE: U.S., 10 pp., Cont.-in-part of U.S. Ser. No. 486,166,  
 abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 11  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6120768	A	20000919	US 1997-990843	19971215
US 5736119	A	19980407	US 1995-409960	19950323
US 5922302	A	19990713	US 1995-440652	19950515
WO 9930745	A2	19990624	WO 1998-US26579	19981215
WO 9930745	A3	20000113		


W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 AU 9918258 A1 19990705 19981215  
 PRIORITY APPLN. INFO.: US 1993-62662 B1 19930517  
 US 1995-409960 A2 19950323  
 US 1995-486166 B2 19950607  
 US 1996-688781 A2 19960731  
 US 1997-990843 A1 19971215  
 WO 1998-US26579 W 19981215

AB A radionuclide-chelator conjugate compn. for detecting and/or treating lesions in a patient comprises pre-targeting the cell, tissue, or pathogen with a substrate, using a targeting protein that specifically binds a marker substance on the target cell, tissue, or pathogen and to which the


L8 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 1  
 (Continued)  
 substrate is directly or indirectly bound. Parenteral injection comprises a chelate conjugate of biotin, a chelator, and a chelatable detection or therapeutic agent, and allows the compn. to accrete at the targeted cell, tissue, or pathogen. The chelate conjugate is purified by liq. chromatog. after chelate formation, or further comprises a blood transit-modifying linker or addend that is covalently bound within the chelate conjugate, or both. The detection or therapeutic agent of the invention are used to detect or treat cancer, infectious diseases, or cardiovascular diseases. Prepn. of biotin-D-Phe-D-Lys-DOTA is presented.  
 IT 7440-54-2D9, Gadolinium, chelates with DOTA-biotin derivs. RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (radionuclide conjugates contg. DOTA-biotin derivs. for diagnosis and therapy)  
 RN 7440-54-2 CAPLUS  
 CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd  
 IT 60239-18-1, DOTA 200402-64-8  
 RL: RCT (Reactant)  
 (radionuclide conjugates contg. DOTA-biotin derivs. for diagnosis and therapy)  
 RN 60239-18-1 CAPLUS  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 1  
 (Continued)




RN 200402-64-8 CAPLUS  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, trisodium salt (9CI) (CA INDEX NAME)



● 3 Na

IT 170908-81-3P 192221-17-3P 192221-18-4P  
 192221-19-5P 245758-39-8P 294637-28-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (radionuclide conjugates contg. DOTA-biotin derivs. for diagnosis and therapy)  
 RN 170908-81-3 CAPLUS  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 1  
 (Continued)



RN 192221-17-3 CAPLUS  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]amino]-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




09/405,046

L8 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2001 ACS  
(Continued)


DUPLICATE 1

PAGE 1-B



RN 192221-18-4 CAPLUS  
CN D-lysineamide,  
N-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-D-phenylalanyl-N6-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]- (9CI) (CA INDEX NAME)  
Absolute stereochemistry.


PAGE 1-A



L8 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2001 ACS  
(Continued)


DUPLICATE 1

PAGE 1-B



RN 245758-39-8 CAPLUS  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]methylamino]ethyl]methylamino]-2-oxoethyl]- (9CI) (CA INDEX NAME)  
Absolute stereochemistry.


PAGE 1-A



L8 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2001 ACS  
(Continued)


DUPLICATE 1

PAGE 1-B



RN 192221-19-5 CAPLUS  
CN D-lysineamide,  
N-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-D-seryl-N6-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]- (9CI) (CA INDEX NAME)  
Absolute stereochemistry.

PAGE 1-A



L8 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2001 ACS  
(Continued)


DUPLICATE 1

PAGE 1-B

CO<sub>2</sub>H

RN 294637-28-8 CAPLUS  
CN D-lysineamide,  
N-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-D-phenylalanyl-D-phenylalanyl-N6-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]- (9CI) (CA INDEX NAME)  
Absolute stereochemistry.

PAGE 1-A




09/405,046

L8 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2001 ACS  
(Continued)

DUPLICATE 1

PAGE 1-B

REFERENCE COUNT:  
REFERENCE(S):

- 31  
(1) Anon; WO 9114458 1991 CAPLUS  
(2) Anon; EP 496074 1992 CAPLUS  
(3) Anon; WO 9325240 1993 CAPLUS  
(4) Anon; WO 9515335 1995 CAPLUS  
(5) Bos; Cancer Research 1994, V54, P3479 CAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 40 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:824136 CAPLUS  
DOCUMENT NUMBER: 133:366464  
TITLE: Macromolecular carrier for drug and diagnostic agent  
INVENTOR(S): Vers, David R.  
PATENT ASSIGNEE(S): The Regents of the University of California, USA  
SOURCE: PCT Int. Appl., 46 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069473	A2	20001123	WO 2000-US13300	20000512
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,				
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-134329 P 19990514  
AB New macromol. carriers for drugs and diagnostic agents are described that make use of the chem. attachment of new leashes to oligomeric backbone structures. The synthesis of these leashes and their facile creation, reaction and conjugation with chelators and ligands makes them ideal candidates for use in medicine, and esp. diagnostics. E.g., dextran was treated with allyl bromide, then cysteamine and the product then attached to DTPA (chelator) for blood pool imaging via MRI or CT.  
IT 7440-54-2DP, Gadolinium, complexes with activated dextran-chelator compds. 60239-18-IDP, Dots, reaction products with activated dextran  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(dextran derivs. for drug and diagnostic agent delivery)  
RN 7440-54-2 CAPLUS

L8 ANSWER 4 OF 40 CAPLUS COPYRIGHT 2001 ACS (Continued)  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

RN 60239-18-1 CAPLUS  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 40 USPATFULL

ACCESSION NUMBER: 2000:94681 USPATFULL  
TITLE: Metal complexes derivatized with folate for use in diagnostic and therapeutic applications  
INVENTOR(S): Vedeking, Paul W., Pennington, NJ, United States  
Wager, Ruth E., Rockville, MD, United States  
Arunachalam, Thangavel, Plainsboro, NJ, United States  
States  
Ramalingam, Kondareddi, Dayton, NJ, United States  
Linder, Karen E., Kingston, NJ, United States  
Ranganathan, Ramachandran S., Princeton, NJ, United States  
Nunn, Adrian D., Lambertville, NJ, United States  
Raju, Natarajan, Kendall Park, NJ, United States  
Tweedle, Michael F., Princeton, NJ, United States  
Bracco Research USA Inc., Princeton, NJ, United States  
PATENT ASSIGNEE(S):  
States  
(U.S. corporation)


	NUMBER	DATE
PATENT INFORMATION:	US 6093382	20000725
APPLICATION INFO.:	US 1998-80157	19980516 (9)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Dees, Jose' G.	
ASSISTANT EXAMINER:	Jones, Dameron	
LEGAL REPRESENTATIVE:	Balogh, Imre	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	3756	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Diagnostic and therapeutic compositions in the form of complexes for enhancing transmembrane transport of a diagnostic or therapeutic agent and methods for their use. The complexes contain the .alpha., .gamma., or his isomers of folate receptor-binding analogs of folate, a metal chelated by a ligand, and in one embodiment, a chemotherapeutic agent.  
IT 251084-37-4P 251084-40-9P 251084-43-2P  
(prepn. and reactant for prepn. of metal complexes for use in diagnostic and therapeutic applications)  
RN 251084-37-4 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[[4-(2-amino-1,4-dihydro-4-oxo-6-pteridiny) methyl] amino] benzoyl] amino]-4-carboxy-1-oxobutyl] amino] phenyl] amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)  
Absolute stereochemistry.


09/405,046

L8 ANSWER 5 OF 40 USPATFULL (Continued)

PAGE 1-A




PAGE 1-B




RN 251084-40-9 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,  
10-[2-[[4-[[[(2S)-2-  
[[4-[[[(2-amino-1,4-dihydro-4-oxo-6-pteridiny]methyl]amino]benzoyl]amino  
]-4-carboxy-1-oxobutyl]amino]phenyl]amino]-2-oxoethyl]- (9CI) (CA  
INDEX NAME)  
Absolute stereochemistry.

L8 ANSWER 5 OF 40 USPATFULL (Continued)

PAGE 1-A




PAGE 1-B




RN 251084-43-2 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,  
10,10'-[[[(2S)-2-[[4-  
[[[(2-amino-1,4-dihydro-4-oxo-6-pteridiny]methyl]amino]benzoyl]amino]-  
1,5-dioxo-1,5-pentenediyl]]bis[(imino-4,1-phenyleneimino(2-oxo-2,1-  
ethanediy]]]]bis- (9CI) (CA INDEX NAME)  
Absolute stereochemistry.

L8 ANSWER 5 OF 40 USPATFULL (Continued)

PAGE 1-A



PAGE 1-B




IT 7440-54-2DP, Gadolinium, complexes with folate-derivatized  
ligands  
(prepn. of metal complexes for use in diagnostic and therapeutic  
applications)

L8 ANSWER 5 OF 40 USPATFULL (Continued)  
RN 7440-54-2 USPATFULL  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

IT 251084-81-8  
(reactant for prepn. of metal complexes for use in diagnostic and  
therapeutic applications)  
RN 251084-81-8 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[4-  
aminophenyl]amino]-2-oxoethyl]-, tris(1,1-dimethylethyl) ester (9CI)  
(CA INDEX NAME)




IT 251084-53-4P 251084-54-5P 251084-55-6P  
251084-56-7P 251084-57-8P 251084-58-9P  
251084-59-0P 251084-60-3P 251084-61-4P  
251084-62-5P 251084-63-6P 251084-64-7P  
(reactant for prepn. of metal complexes for use in diagnostic and  
therapeutic applications)  
RN 251084-53-4 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,  
10-[2-[[4-[[[(4S)-5-  
(1,1-dimethylethoxy)-1,5-dioxo-4-[[[phenylmethoxy]carbonyl]amino]pentyl]  
amino]phenyl]amino]-2-oxoethyl]-, tris(1,1-dimethylethyl) ester  
(9CI)  
(CA INDEX NAME)  
Absolute stereochemistry.



09/405,046


L8 ANSWER 5 OF 40 USPATFULL (Continued)



PAGE 2-A


RN 251084-54-5 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,  
10-[2-[[4-[[[(4S)-4-amino-5-(1,1-dimethylethoxy)-1,5-dioxopentyl]amino]phenyl]amino]-2-oxoethyl]-, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)  
Absolute stereochemistry.

L8 ANSWER 5 OF 40 USPATFULL (Continued)




RN 251084-55-6 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,  
10-[2-[[4-[[[(4S)-4-[[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]amino]-5-(1,1-dimethylethoxy)-1,5-dioxopentyl]amino]phenyl]amino]-2-oxoethyl]-, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)  
Absolute stereochemistry.

PAGE 1-A




L8 ANSWER 5 OF 40 USPATFULL (Continued)

PAGE 1-B




RN 251084-56-7 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,  
10-[2-[[4-[[[(4S)-4-[[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]amino]-5-(1,1-dimethylethoxy)-1,5-dioxopentyl]amino]phenyl]amino]-2-oxoethyl]-, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)  
Absolute stereochemistry.

PAGE 1-A




L8 ANSWER 5 OF 40 USPATFULL (Continued)

PAGE 1-B



RN 251084-57-8 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,  
10-[2-[[4-[[[(2S)-5-[(1,1-dimethylethoxy)-1,5-dioxo-2-[[[(phenylmethoxy)carbonyl]amino]pentyl]amino]phenyl]amino]-2-oxoethyl]-, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)  
Absolute stereochemistry.



PAGE 1-A



09/405,046

L8 ANSWER 5 OF 40 USPATFULL (Continued)


PAGE 2-A




LN 251084-59-0 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,  
 10-[2-[[4-[(2S)-2-  
 [[4-[[[2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl](trifluoroacetyl)am  
 ino]benzoyl]amino]-5-(1,1-dimethylethoxy)-1,5-  
 dioxopentyl]amino]phenyl]amino]-2-oxoethyl]-,  
 tris(1,1-dimethylethyl)  
 ester (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

L8 ANSWER 5 OF 40 USPATFULL (Continued)

PAGE 1-A



PAGE 1-B



```


RN      251084-61-4    USPATFULL
CN      1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
10,10'-[[2,2,1,5-
dioxo-2'-[[[phenylmethoxy]carbonyl]amino]-1,5-pentanediy]]bis[imino-4,1-
phenyleneimino(2-oxo-2,1-ethanediy)]bis-,
hexakis(1,1-dimethylethyl)
ester (SCI)      (CA INDEX NAME)

Absolute stereochemistry.


```

L8 ANSWER 5 OF 40 USPATFULL (Continued)

PAGE 1-A



PAGE 1-B



```


CN      251084-60-3  USPATFULL
PM      1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
10-[2-[[4-[[[(2S)-2-
[[[4-[[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]amino
]-5-(1,1-dimethylethyl)-1,5-dioxopentyl]amino]phenyl]amino]-2-oxoethyl]-
, tris(1,1-dimethylethyl) ester (9CI)      (CA INDEX NAME)

Absolute stereochemistry.


```

L8 ANSWER 5 OF 40 USPATFULL (Continued)

PAGE 1-A



PAGE 2-A




RN 251084-62-5 USPATYFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,  
10,10'-[[2,5-diamino-  
(1,5-dioxo-1,5-pentanediyldi)bis[imino-4,1-phenyleneimino(2-oxo-2,1-  
ethanediyldi)]]bis-, hexakis(1,1-dimethylethyl) ester (9CI) (CA INDEX  
NAME)  
  
Absolute stereochemistry.


09/405,046

L8 ANSWER 5 OF 40 USPATFULL (Continued)

PAGE 1-A




PAGE 2-A




RN 251084-63-6 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,  
10,10'-[[[(2S)-2-[[4-  
[[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyloxy)methyl]amino]benzoyl]amino]-1,5-dioxo-1,5-pentanediyloxy]bis[imino-4,1-phenyleneimino(2-oxo-2,1-ethanediyloxy)]bis-, hexakis(1,1-dimethylethyl) ester (9CI)  
(CA INDEX NAME)

L8 ANSWER 5 OF 40 USPATFULL (Continued)


PAGE 1-B



PAGE 2-A



PAGE 2-B




RN 251084-64-7 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,  
10,10'-[[[(2S)-2-[[4-  
[[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyloxy)methyl]amino]benzoyl]amino]-

L8 ANSWER 5 OF 40 USPATFULL (Continued)

Absolute stereochemistry.


PAGE 1-A



L8 ANSWER 5 OF 40 USPATFULL (Continued)  
1,5-dioxo-1,5-pentanediyloxy]bis[imino-4,1-phenyleneimino(2-oxo-2,1-ethanediyloxy)]bis-, hexakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




09/405,046

L8 ANSWER 5 OF 40 USPATFULL (Continued)


PAGE 1-B



PAGE 2-A



PAGE 2-B



L8 ANSWER 6 OF 40 USPATFULL

ACCESSION NUMBER: 2000:91563 USPATFULL  
 TITLE: Use of polymerized lipid diagnostic agents  
 INVENTOR(S): Li, King Chuen, Stanford, CA, United States  
 Bednarski, Mark David, Los Altos, CA, United States  
 Storrs, Richard Wood, San Diego, CA, United States  
 Li, Henry Y., Visalia, CA, United States  
 Tropper, Francois Daniel, Toronto, Canada  
 Song, Curtis Kang Hoon, Sunnyvale, CA, United States  
 States: Sipkins, Dorothy Anna, Palo Alto, CA, United States  
 Kuniyoshi, Jeremy Kenji, Cupertino, CA, United States  
 STATES PATENT ASSIGNEE(S): Targesome, Inc., Palo Alto, CA, United States (U.S. corporation)


	NUMBER	DATE
PATENT INFORMATION:	US 6090408	20000718
APPLICATION INFO.:	US 1998-122807	19980727 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-629056, filed on 8 Apr 1996 which is a continuation-in-part of Ser. No. US 1994-286555, filed on 5 Aug 1994, now patented,	

Pat. No. US 5512294, issued on 30 Apr 1996  
 DOCUMENT TYPE: Utility  
 PRIMARY EXAMINER: Kishore, Gollamudi S.  
 LEGAL REPRESENTATIVE: Morrison & Foerster LLP  
 NUMBER OF CLAIMS: 24  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 37 Drawing Figure(s); 26 Drawing Page(s)  
 LINE COUNT: 1530  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Polymerized liposome particles which are linked to a targeting agent and may also be linked to a contrast enhancement agent and/or linked to or encapsulating a treatment agent. The targeting imaging enhancement polymerized liposome particles interact with biological targets holding the image enhancement agent to specific sites providing in vitro and in vivo study by magnetic resonance, radioactive, x-ray or optical imaging of the expression of molecules in cells and tissues during disease and pathology. Targeting polymerized liposomes may be linked to or encapsulate a treatment agent, such as, proteins, drugs or hormones for directed delivery to specific biological sites for treatment.

IT 60239-18-1, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (synthetic lipids prepd. from targeted polymd. liposome contrast agents)  
 RN 60239-18-1 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX

L8 ANSWER 5 OF 40 USPATFULL (Continued)

L8 ANSWER 6 OF 40 USPATFULL (Continued)  
 NAME)



IT 7440-54-2DP, Gadolinium, complexes with synthetic lipids (targeted polymd. liposome contrast agents)  
 RN 7440-54-2 USPATFULL  
 CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

09/405,046


L8 ANSWER 7 OF 40 USPATFULL  
 ACCESSION NUMBER: 2000:27541 USPATFULL  
 TITLE: Biomodulators as universal imaging agents  
 INVENTOR(S): Born, Jerry L., Albuquerque, NM, United States  
 Eshima, Dennis, Albuquerque, NM, United States  
 Mann, Paul L., Albuquerque, NM, United States  
 Matwyoff, Nicholas A., Albuquerque, NM, United States  
 States  
 PATENT ASSIGNEE(S): University of New Mexico, Albuquerque, NM, United States (U.S. corporation)  
 NUMBER DATE  
 PATENT INFORMATION: US 6033644 20000307  
 APPLICATION INFO.: US 1998-186096 19981105 (9)  
 RELATED APPLN. INFO.: Division of Ser. No. US 1995-405017, filed on 16 Mar 1995, now patented, Pat. No. US 5906807 which is a division of Ser. No. US 1991-694325, filed on 1 May 1991, now patented, Pat. No. US 5401489  
 DOCUMENT TYPE: Utility  
 PRIMARY EXAMINER: Dees, Jose' G.  
 ASSISTANT EXAMINER: Hartley, Michael G.  
 LEGAL REPRESENTATIVE: Evans, Judith A. Dovetail Technologies Inc.  
 NUMBER OF CLAIMS: 14  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 10 Drawing Figure(s); 9 Drawing Page(s)  
 LINE COUNT: 1043  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Biomodulators, optionally linked to imaging-active moieties, can be administered to a host to enhance images thereof, e.g., NMR-, X-ray- or radio-images, preferably by increasing aberrant tissue signal intensity. Biomodulators can also condition tissue to enhance uptake of otherwise non-specific imaging agents. When linked to drugs, biomodulators can target the same to particular sites in the body.  
 IT 7440-54-2D, Gadolinium, complexes with DTPA-galactose (tissue MRI enhancement with biomodulator and)  
 RN 7440-54-2 USPATFULL  
 CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

IT 60239-18-1D, DOTA, saccharide conjugates, metal complexes (tissue imaging with, biomodulator enhancement of)  
 RN 60239-18-1 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

L8 ANSWER 8 OF 40 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.  
 ACCESSION NUMBER: 2000321753 EMBASE  
 TITLE: A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling.  
 AUTHOR: Eisenwiener K.-P.; Powell P.; Macke H.R.  
 CORPORATE SOURCE: H.R. Macke, Division of Radiological Chemistry, Institute of Nuclear Medicine, Department of Radiology, Petersgraben 4, CH-4031 Basel, Switzerland. hmaecke@uhbs.ch  
 SOURCE: Bioorganic and Medicinal Chemistry Letters, (2000) 10/18 (2133-2135).  
 Refs: 11  
 ISSN: 0960-894X CODEN: BMCLES  
 PUBLISHER IDENT.: S 0960-894X(00)00413-3  
 COUNTRY: United Kingdom  
 DOCUMENT TYPE: Journal: Article  
 FILE SEGMENT: 014 Radiology  
 023 Nuclear Medicine  
 037 Drug Literature Index  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English  
 AB New DOTA-based bifunctional prochelators, e.g., 1-(1-carboxy-3-carbotertbutoxypropyl)-4,7,10-(carbotertbutoxymethyl)-1,4,7,10-tetraazacyclododecane (DOTAGA(tBu)4), (6d) for a broad application in the modification of biomolecules with metal ions were prepared. The five-step synthesis of 6d has an overall yield of about 20%. The coupling of 6d to a bioactive peptide on solid-phase was exemplified with use of a CCK-B (cholecystokinin) analogue. (C) 2000 Elsevier Science Ltd.

L8 ANSWER 7 OF 40 USPATFULL (Continued)



L8 ANSWER 9 OF 40 CAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1999:819407 CAPLUS  
 DOCUMENT NUMBER: 132:61087  
 TITLE: Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy  
 INVENTOR(S): Pivnicka-Worms, David  
 PATENT ASSIGNEE(S): Washington University, USA  
 SOURCE: PCT Int. Appl., 6S pp. CODEN: PIXX02  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:  

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9967284	A2	19991229	WO 1999-US13660	19990618
WO 9967284	A3	20000406		


V: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 AU 9946905 A1 20000110 AU 1999-46905 19990618  
 EP 1090032 A2 20010411 EP 1999-930351 19990618  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE, FI  
 PRIORITY APPLN. INFO.: US 1998-90087 P 19980620  
 WO 1999-US13660 W 19990618  
 AB Methods and compns. for medical imaging, evaluating intracellular processes and components, radiotherapy of intracellular targets, and drug delivery by the use of novel cell membrane-permeant peptide conjugate coordination and covalent complexes having target cell specificity are provided. Kits for conjugating radionuclides and other metals to peptide coordination complexes are also provided.  
 IT 7440-54-2D, Gadolinium, complexes of paramagnetic isotopes  
 60239-18-1D, DOTA, peptide conjugates, complexes  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy)  
 RN 7440-54-2 CAPLUS  
 CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

09/405,046

L8 ANSWER 9 OF 40 CAPLUS COPYRIGHT 2001 ACS (Continued)

Gd

RN 60239-18-1 CAPLUS  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)




L8 ANSWER 10 OF 40 USPATFULL  
ACCESSION NUMBER: 1999:141269 USPATFULL  
TITLE: Magnetic resonance imaging agents for the detection of physiological agents  
INVENTOR(S): Meade, Thomas, Altadena, CA, United States  
Fraser, Scott, La Canada, CA, United States  
Jacobs, Russell, Arcadia, CA, United States  
Li, Wenhong, Pasadena, CA, United States  
Research Corporation Technologies, Tucson, AZ, United States (U.S. corporation)  
NUMBER DATE  
PATENT INFORMATION: US 5980862 19991109  
APPLICATION INFO.: US 1998-134072 19980813 (9)  
RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-460511, filed on 2 Jun 1995, now abandoned Ser. No. Ser. No. US 1995-486968, filed on 7 Jun 1995, now patented, Pat. No. US 5707605 And Ser. No. US 971855

NUMBER DATE  
PRIORITY INFORMATION: US 1997-63328 19971027 (60)  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Clardy, S. Mark  
ASSISTANT EXAMINER: Jones, Dameron  
LEGAL REPRESENTATIVE: Flehr Hohbach Test Albritton & Herbert; Treccartin, Esq., Richard F.; Silva, Esq., Robin M.  
NUMBER OF CLAIMS: 33  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 26 Drawing Figure(s); 15 Drawing Page(s)  
LINE COUNT: 2068  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention relates to novel magnetic resonance imaging contrast agents and methods of detecting physiological signals or substances.  
IT 7440-54-2B, Gadolinium, chelate complexes contg. covalently-attached blocking moiety (as MRI contrast agents for detection of physiol. agents)  
RN 7440-54-2 USPATFULL  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd


IT 60239-18-1, DOTA  
(chelator for prepn. of MRI contrast agents)  
RN 60239-18-1 USPATFULL

L8 ANSWER 10 OF 40 USPATFULL (Continued)  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L8 ANSWER 11 OF 40 USPATFULL  
ACCESSION NUMBER: 1999:137312 USPATFULL  
TITLE: Water soluble paclitaxel prodrugs  
INVENTOR(S): Li, Chun, Missouri City, TX, United States  
Wallace, Sidney, Houston, TX, United States  
Yu, Dong-Fang, Houston, TX, United States  
Yang, David J., Sugar Land, TX, United States  
PG-TXL Company, L. P., Houston, TX, United States (U.S. corporation)  
NUMBER DATE  
PATENT INFORMATION: US 5977163 19991102  
APPLICATION INFO.: US 1997-815104 19970311 (8)

NUMBER DATE  
PRIORITY INFORMATION: US 1996-13184 19960312 (60)  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Dees, Jose' G.  
ASSISTANT EXAMINER: Hartley, Michael G.  
LEGAL REPRESENTATIVE: Arnold White & Durkee  
NUMBER OF CLAIMS: 22  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 11 Drawing Page(s)  
LINE COUNT: 1268  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble chelator, polyethylene glycol or polymer such as poly (l-glutamic acid) or poly (l-aspartic acid). Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis and for prediction of paclitaxel uptake by tumors and radiolabeled DTPA-paclitaxel tumor imaging. Other embodiments include the coating of implantable stents for prevention of restenosis.  
IT 60239-18-1, DOTA  
(chelator; water sol. paclitaxel prodrugs)  
RN 60239-18-1 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



09/405,046

L8 ANSWER 11 OF 40 USPATFULL (Continued)

IT 7440-54-2, Gadolinium, biological studies  
(water sol. paclitaxel prodrugs)  
RN 7440-54-2 USPATFULL  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

L8 ANSWER 12 OF 40 USPATFULL

ACCESSION NUMBER: 1999:132199 USPATFULL  
TITLE: Dichelants  
INVENTOR(S): Carvalho, Joan, Mountain View, CA, United States  
Watson, Alan D., Campbell, CA, United States  
Fellmann, Jere D., Livermore, CA, United States  
Koo, Michael, San Jose, CA, United States  
Mycomed Salutar, Inc., Wayne, PA, United States  
PATENT ASSIGNEE(S):  
(U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5972307	19991026
APPLICATION INFO.:	US 1997-898376	19970722 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-226760, filed on 12 Apr	
	1994, now patented, Pat. No. US 5650133 which is a continuation-in-part of Ser. No. US 1993-86996,	
filed	on 7 Jul 1993, now patented, Pat. No. US 5446145	
which	is a continuation-in-part of Ser. No. US	
1990-468107,	filed on 19 Jan 1990, now patented, Pat. No. US	
5281704	, said Ser. No. US 226760 which is a continuation-in-part of Ser. No. US 1992-885028,	
filed	on 12 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 468107	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1993-20277	19931001
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Dees, Jose' G.	
ASSISTANT EXAMINER:	Hartley, Michael G.	
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1802	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	This invention relates to dichelants, in particular compounds having two macrocyclic chelant groups linked by a bridge containing an ester or amide bond, especially compounds of formula Vb ##STR1## (wherein each X which may be the same or different is N2, O or S, at least two Xs being N2;	
	each Z is a group R.sup.1 or a group CR.sup.1.sub.2 Y, at least one Z,	

L8 ANSWER 12 OF 40 USPATFULL (Continued)

and preferably 2 or 3 Zs, on each macrocyclic ring being a group CR.sup.1.sub.2 Y;

each Y is a group CO.sub.2 H, PO.sub.3 H, SO.sub.3 H,

CONR.sup.1.sub.2, CON(OR.sup.1)R.sup.1, CNS or CONR.sup.1 NR.sup.1.sub.2, preferably COOH;

m is 0 or 1 or 2, preferably 1; each n is 2 or 3, preferably 2; q is 1 or 2, preferably 1;

each R.sup.1 which may be the same or different is a hydrogen atom or an alkyl group optionally substituted by one or more hydroxy and/or alkoxy groups;

and D is a bridging group having a molecular weight of less than 1000, preferably less than 500, joining two macrocyclic rings via at least one amide or ester bond) and salts and metal chelates thereof.


IT 137076-40-5 137097-99-5 (chelating agent, polychelant)

RN 137076-40-5 USPATFULL


CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-(1,2-ethanediylbis[imino(2-oxo-2,1-ethanediyl)])bis-, hexaethyl ester (9CI)

(CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 137097-99-5 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-(1,2-ethanediylbis[imino(2-oxo-2,1-ethanediyl)])bis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 7440-54-2, Gadolinium, reactions (complexation of, chelating agent for)

RN 7440-54-2 USPATFULL


CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd


IT 137076-50-7P 137076-51-8P 137076-54-1P (prepn. of, in polychelant chelating agent prepn.)

09/405,046

L8 ANSWER 12 OF 40 USPATFULL (Continued)  
 RN 137076-50-7 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tetraethyl ester (9CI) (CA INDEX NAME)




RN 137076-51-8 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, triethyl ester, potassium salt (9CI) (CA INDEX NAME)



● K

RN 137076-54-1 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

L8 ANSWER 12 OF 40 USPATFULL (Continued)



L8 ANSWER 13 OF 40 USPATFULL  
 ACCESSION NUMBER: 1999:116945 USPATFULL  
 TITLE: Low viscosity chelating polymers for diagnostic imaging  
 INVENTOR(S): Ladd, David L., Wayne, PA, United States  
 PATENT ASSIGNEE(S): Nycomed Imaging AS, Norway (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5958372	19990928
APPLICATION INFO.:	US 1994-266835	19940628 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Hollinden, Gary E.	
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	849	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Disclosed are linear and cross-linked polymers suitable for use as a contrast agent for magnetic resonance imaging containing units comprising the residue of a poly(amine) moiety linked to a chelating agent and to one or more pendant (poly)alkylene oxides.

IT 7440-54-2D, Gadolinium, chelates with polyamine-polyalkylene oxide-chelating agent 60239-18-1D, DOTA, polyamine-polyalkylene oxide reaction products (chelating polymer prepn. and use as MRI contrast agent)

RN 7440-54-2 USPATFULL  
 CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

RN 60239-18-1 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L8 ANSWER 14 OF 40 USPATFULL  
 ACCESSION NUMBER: 1999:69485 USPATFULL  
 TITLE: Polychelants containing amide bonds  
 INVENTOR(S): Watson, Alan D., Campbell, CA, United States  
 PATENT ASSIGNEE(S): Salutar, Inc., Sunnyvale, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5914095	19990622
APPLICATION INFO.:	US 1991-772349	19911007 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1990-EP9100565, filed on 5 Apr 1990 And Ser. No. US 1990-464865, filed on 16 Jan 1990, now patented, Pat. No. US 5364613	
which	is a continuation-in-part of Ser. No. US 1989-335162,	
	filed on 7 Apr 1989, now abandoned	

DOCUMENT TYPE: Utility  
 PRIMARY EXAMINER: Hollinden, Gary E.  
 LEGAL REPRESENTATIVE: Fish & Richardson P.C.  
 NUMBER OF CLAIMS: 23  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 1338

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are provided polychelants and their metal chelates which are useful in diagnostic imaging and in radiotherapy and which comprise

a plurality of macrocyclic chelant moieties, e.g. DOTA residues, conjugated to a dendritic polyamine backbone molecule, e.g. a starburst dendrimer. To produce a site-specific polychelate, one or more of the macrocyclic chelant carrying backbone molecules may be conjugated to a site-directed macromolecule, e.g. a protein.

IT 7440-54-2D, Gadolinium, starburst dendritic polymer-macrocyclic chelates 60239-18-1D, conjugates with starburst dendritic polymers, metal complexes 150467-20-2D, conjugates with starburst dendritic polymers, metal complexes 151790-71-5D, conjugates with starburst dendritic polymers, metal complexes (for diagnostic imaging and radiotherapy)

RN 7440-54-2 USPATFULL  
 CN Gadolinium (8CI, 9CI) (CA INDEX NAME)


Gd

RN 60239-18-1 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)




09/405,046

L8 ANSWER 14 OF 40 USPATFULL (Continued)




RN 150467-20-2 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-aminoethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 151790-71-5 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-(4-aminophenyl)ethyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 14 OF 40 USPATFULL (Continued)



L8 ANSWER 14 OF 40 USPATFULL (Continued)

PAGE 1-A



PAGE 2-A



IT 60239-18-1, DOTA  
(reaction of, with iso-Bu chloroformate)  
RN 60239-18-1 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

L8 ANSWER 15 OF 40 USPATFULL

ACCESSION NUMBER: 1999:60994 USPATFULL  
TITLE: Method of MRI using biomodulators  
INVENTOR(S): Born, Jerry L., Albuquerque, NM, United States  
Eshima, Dennis, Albuquerque, NM, United States  
Mann, Paul L., Albuquerque, NM, United States  
Matviyoff, Nicholas A., Albuquerque, NM, United States  
States  
PATENT ASSIGNEE(S): University of New Mexico, Albuquerque, NM, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5906807	19990525
APPLICATION INFO.:	US 1995-405017	19950316 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1991-694325, filed on 1 May 1991, now patented, Pat. No. US 5401489, issued on 28 Mar 1995	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Hollinden, Gary E.	
ASSISTANT EXAMINER:	Hartley, Michael G.	
LEGAL REPRESENTATIVE:	Jones & Volentine, L.L.P.	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 9 Drawing Page(s)	
LINE COUNT:	983	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Biomodulators, optionally linked to imaging-active moieties, can be administered to a host to enhance images thereof, e.g., NMR-, X-ray- or radio-images, preferably by increasing aberrant tissue signal intensity. Biomodulators can also condition tissue to enhance uptake of otherwise non-specific imaging agents. When linked to drugs, biomodulators can target the same to particular sites in the body.

IT 7440-54-2D, Gadolinium, complexes with DTPA-galactose (tissue MRI enhancement with biomodulator and)


RN 7440-54-2 USPATFULL  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

IT 60239-18-1D, DOTA, saccharide conjugates, metal complexes (tissue imaging with, biomodulator enhancement of)  
RN 60239-18-1 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

09/405,046

L8 ANSWER 15 OF 40 USPATFULL (Continued)




L8 ANSWER 16 OF 40 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 2  
ACCESSION NUMBER: 1998:623984 CAPLUS  
DOCUMENT NUMBER: 129:250213  
TITLE: Biotinidase-resistant biotinylated compound and methods of use thereof  
INVENTOR(S): Rosebrough, Scott F.  
PATENT ASSIGNEE(S): University of Rochester, USA  
SOURCE: U.S., 21 pp. Cont.-in-part of U.S. 5,326,778.  
CODEN: USKXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5807879	A	19980915	US 1994-221113	19940331
US 5326778	A	19940705	US 1992-845416	19920303
AT 160700	E	19971215	AT 1993-906281	19930303
			US 1992-845416	19920303

PRIORITY APPLN. INFO.:  
OTHER SOURCE(S): MARPAT 129:250213  
AB The present invention provides biotinylated compds. useful for delivering a mol. to a target site, and methods of making biotinylated compds.  
The biotinylated compds. are covalent conjugates of biotin and a diagnostic or therapeutic agent, and are stable to rapid degradn. by biotinidase.  
The compds. of the invention are useful for delivering therapeutic or diagnostic agents to target-bound streptavidin or avidin conjugated cell-targeting agents, including monoclonal antibodies. The compd. N-cysteinyl biotin is also provided. One example given is for the prepn. of biotin-cysteine-ethylamine-Bolton Hunter.  
IT 7440-54-2D, Gadolinium, complexes  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (biotinidase-resistant biotinylated compd.)  
RN 7440-54-2 CAPLUS  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

IT 60239-18-1, DOTA  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (chelating agent; biotinidase-resistant biotinylated compd.)  
RN 60239-18-1 CAPLUS  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

L8 ANSWER 16 OF 40 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 2  
(Continued)

L8 ANSWER 17 OF 40 CAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1998:721606 CAPLUS  
DOCUMENT NUMBER: 130:7446  
TITLE: Stents with a radioactive surface coating, their production and use for restenosis prevention  
INVENTOR(S): Dinkelborg, Ludger; Blume, Friedhelm; Hilger, Christoph-Stephan; Heidmann, Dieter; Platzek, Johannes; Niedballa, Ulrich; Miklautz, Heribert; Speck, Ulrich; Duda, Stephan; Tepe, Gunnar; Noll, Bernhard; Goerner, Heidmarie  
PATENT ASSIGNEE(S): Schering A.-G., Germany  
SOURCE: PCT Int. Appl., 42 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9848851	A2	19981105	WO 1998-EP2527	19980429
WO 9848851	A3	19990422		
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19724230	C1	19981126	DE 1997-19724230	19970603
DE 19724223	C1	19981224	DE 1997-19724223	19970603
DE 19724229	C1	19990401	DE 1997-19724229	19970603
AU 9879100	A1	19981124	AU 1998-79100	19980429
EP 979108	A2	20000216	EP 1998-929272	19980429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE, FI				
NO 9905310	A	19991029	NO 1999-5310	19991029


PRIORITY APPLN. INFO.:  
AB The surface of a metallic stent is coated with a radioactive metal isotope by chem. deposition (redn. or pptn.) or electrodeposition, or by chelation with a compd. which adheres to the stent (e.g. a peptide or lipid). Alternatively, the stent may be coated electrochem. with Au and then with a SH group-contg. chelate of a radioactive metal, where the SH

09/405,046

L8 ANSWER 17 OF 40 CAPLUS COPYRIGHT 2001 ACS (Continued)  
group-contg. complexing agent adheres to the Au coating. Thus, a  
Wiktor  
stent was immersed in 1 mL EtOH soln. of 1-[3-[N-(2-  
methoxyethyl)octadecylsulfamoyl]-2-hydroxypropyl]-4,7,10-  
tris(hydroxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane, 2 mL H<sub>2</sub>O  
was  
added, and the stent was sonicated for 15 min, removed, and dried.  
The  
coated stent was then immersed in 2 mL 0.9% NaCl soln., 37 MBq  
111InCl<sub>3</sub>  
was added, and the stent was sonicated for 15 min, rinsed in NaCl  
soln.,  
and dried. The labeled stent had an activity of 1.49 MBq 111In.  
IT 7440-54-2D, Gadolinium, radioisotopes  
RL: DEV (Device component use); THU (Therapeutic use); BIOL  
(Biological  
study); USES (Uses)  
(coating contg.; stents with radioactive surface coating for  
restenosis  
prevention)  
RN 7440-54-2 CAPLUS  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

IT 60239-18-1D, DOTA, reaction products with hydroxysulfosuccinimide  
and aminoundecanethiol, indium-111 complexes 215604-06-1  
RL: DEV (Device component use); THU (Therapeutic use); BIOL  
(Biological  
study); USES (Uses)  
(stents with radioactive surface coating for restenosis prevention)  
RN 60239-18-1 CAPLUS  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA  
INDEX  
NAME)




RN 215604-06-1 CAPLUS  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,

L8 ANSWER 18 OF 40 CAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1998:542995 CAPLUS  
DOCUMENT NUMBER: 129:158579  
TITLE: Method using radioactive metal or paramagnetic  
metal-labeled neurotensin compounds for the  
detection,  
localization, and treatment of malignant human  
tumors  
INVENTOR(S): Reubi, J. C.  
PATENT ASSIGNEE(S): Mallinckrodt Medical, Inc., USA  
SOURCE: PCT Int. Appl., 33 pp.  
CODEN: PIXXD2  
Patent  
DOCUMENT TYPE: English  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9833531	A1	19980806	WO 1998-US1964	19980202
W: AL, AU, BA, BB, BG, BR, CA, CH, CU, CZ, EE, GE, GW, HU, ID,				
IL,		IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ,		
PL,		RO, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG,		
KZ,		MD, RU, TJ, TM		
FI,		RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES,		
CH,		FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,		
		GA, GN, ML, MR, NE, SN, TD, TG		
AU 9862622	A1	19980825	AU 1998-62622	19980202
AU 728712	B2	20010118		
EP 968001	A1	20000105	EP 1998-904839	19980202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
NO 9903846	A	19990909	NO 1999-3846	19990810
PRIORITY APPLN. INFO.:		EP 1997-200297	A	19970203
		WO 1998-US1964	W	19980202

OTHER SOURCE(S): MARPAT 129:158579  
AB A method is disclosed for detecting and localizing malignant tumors  
and  
their metastases in tissues, which in healthy condition and in  
non-neoplastic conditions of chronic inflammation do not contain  
substantial quantities of neurotensin-receptors, in the body of a  
human  
being. The method comprises: (i) administering a compn. comprising,  
in a  
quantity sufficient for external imaging, a (radio)labeled peptide  
selected from the group consisting of neurotensin (NT), NT-receptor  
agonists, NT-receptor antagonists, NT analogs and NT derivs.; and  
thereupon (ii) subjecting said being to external imaging, by  
radioactive  
scanning or by magnetic resonance imaging, to det. the targeted sites  
in  
the body. The invention further relates to a method for the  
therapeutic


L8 ANSWER 17 OF 40 CAPLUS COPYRIGHT 2001 ACS (Continued)  
mono[(4-thiocyanatophenyl)methyl] ester (9CI) (CA INDEX NAME)



L8 ANSWER 18 OF 40 CAPLUS COPYRIGHT 2001 ACS (Continued)  
treatment of the malignant tumors by administration of the above  
peptide, labeled for this purpose, and to the differential-  
diagnostic assessment and detection of a specific tumor type (i.e.  
ductal  
exocrine pancreatic carcinoma) of the pancreas. The invention also  
relates to a pharmaceutical compn. to be used for detection, a  
pharmaceutical compn. to be used for therapy and to a kit for prep. a  
radiopharmaceutical compn.  
IT 7440-54-2D, Gadolinium, neurotensin compd. reaction products  
60239-18-1D, DOTA, chelates, neurotensin compd. reaction products  
RL: BAC (Biological activity or effector, except adverse); BPR  
(Biological  
process); THU (Therapeutic use); BIOL (Biological study); PROC  
(Process);  
USES (Uses)  
(radioactive metal or paramagnetic metal-labeled neurotensin  
comps.  
for detection, localization, and treatment of malignant human  
tumors)  
RN 7440-54-2 CAPLUS  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

RN 60239-18-1 CAPLUS  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA  
INDEX  
NAME)



09/405,046

L8 ANSWER 19 OF 40 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:251081 CAPLUS

DOCUMENT NUMBER: 128:318919

TITLE: Integrin-binding compound conjugates with paramagnetic

metal chelators for magnetic resonance imaging of thrombi  
INVENTOR(S): Tolley, James O.; Mazur, Paul Curtis; Mullen, DanielG.; Pierschbacher, Michael D.; Tschopp, Juerg  
PATENT ASSIGNEE(S): Burnham Institute, USA

PCT Int. Appl., 65 pp.

SOURCE: CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9816256	A1	19980423	WO 1997-US18412	19971015
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				

PT, SE AU 9747539 A1 19980511 AU 1997-47539 19971015

PRIORITY APPLN. INFO.: US 1996-732043 19961016  
WO 1997-US18412 19971015

OTHER SOURCE(S): MARPAT 128:318919

AB Magnetic resonance imaging (MRI) contrast agents useful for detecting thrombi are provided. The MRI contrast agents comprise a chelator capable of complexing a paramagnetic metal, which chelator is coupled to a chem.

compd., e.g. a peptide, capable of binding to an integrin. The MRI contrast agent can addnl. contain the paramagnetic metal which complexes with the chelator. Compns. contg. these MRI agents and a physiol. acceptable carrier, as well as the use of such agents to detect thrombus in a subject, are also provided by the present invention.

IT 7440-54-2D, Gadolinium, chelates, peptide conjugates  
60239-18-1D, DOTA, peptide conjugatesRL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Integrin-binding compd. conjugates with paramagnetic metal

chelators for MRI of thrombi)

RN 7440-54-2 CAPLUS

CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

RN 60239-18-1 CAPLUS

L8 ANSWER 20 OF 40 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:98351 CAPLUS

DOCUMENT NUMBER: 128:172129

TITLE: Improved detection and therapy of lesions with biotin-chelate conjugates

Griffiths, Gary L.; Hansen, Hans J.; Karacay, Habib

PATENT ASSIGNEE(S): Immunomedics, Inc., USA; Griffiths, Gary L.; Hansen,

Hans J.; Karacay, Habib

PCT Int. Appl., 38 pp.

SOURCE: CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 11

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9804293	A1	19980205	WO 1997-US13285	19970731
W: AL, AM, AT, AU, AZ, BA, BB, BG, ER, BY, CA, CH, CN, CU, CZ,				

DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ,

LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,

PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,

UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,

FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,

GA, GN, ML, MR, NE, SN, TD, TG

AU 9740474 A1 19980220 AU 1997-40474 19970731

PRIORITY APPLN. INFO.: US 1996-688781 A2 19960731

WO 1997-US13285 W 19970731

AB An improved method of detecting and/or treating lesions in a patient

in which a pre-targeting approach is used wherein the total amt. of

radionuclide delivered to a target cell, tissue, or pathogen is

dramatically increased. In this method, the chelate conjugate may be

purified by chromatog. after chelate formation, may contain multiple

chelates or a blood transit-modifying linker or added within the

chelate conjugate, or both or a combination of these. The improved chelate

conjugates can be used as detection of therapeutic agents to detect or

treat the targeted cell, tissue, or pathogen.

Biotin-D-Phe-D-Lys-DOTA was

prepd. and complexed with gadolinium for MRI.

IT 200402-64-8

RL: RCT (Reactant)

(detection and therapy of lesions with biotin-chelate conjugates)

RN 200402-64-8 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, trisodium

salt


(9CI) (CA INDEX NAME)

L8 ANSWER 19 OF 40 CAPLUS COPYRIGHT 2001 ACS (Continued)


CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA

INDEX

NAME)



L8 ANSWER 20 OF 40 CAPLUS COPYRIGHT 2001 ACS (Continued)



● 3 Na

IT 7440-54-2DP, Gadolinium, complexes with biotin-peptide

-chelating agents 170908-81-3P 202932-81-2DP,

complexes with radionuclides

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(detection and therapy of lesions with biotin-chelate conjugates)

RN 7440-54-2 CAPLUS


CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

RN 170908-81-3 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,

10-[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 202932-51-2 CAPLUS

CN D-lysineamide,

N-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-


4-yl]-1-oxopentyl]-D-phenylalanyl-N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-

09/405,046


L8 ANSWER 20 OF 40 CAPLUS COPYRIGHT 2001 ACS (Continued)  
tetraazacyclododec-1-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



L8 ANSWER 21 OF 40 USPATFULL (Continued)  
(chelator for prepn. of MRI contrast agents)  
RN 60239-18-1 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L8 ANSWER 21 OF 40 USPATFULL  
ACCESSION NUMBER: 1998:4212 USPATFULL  
TITLE: Magnetic resonance imaging agents for the detection of physiological agents  
INVENTOR(S): Meade, Thomas, Altadena, CA, United States  
Fraser, Scott, Newport Beach, CA, United States  
Jacobs, Russell, Arcadia, CA, United States  
PATENT ASSIGNEE(S): Research Corporation Technologies, Tucson, AZ, United States (U.S. corporation)

NUMBER	DATE
US 5707605	19980113
US 1995-486968	19950607 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-460511, filed on 2 Jun 1995, now abandoned

DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Kight, John  
ASSISTANT EXAMINER: Jones, Dameron L.  
LEGAL REPRESENTATIVE: Flehr Hobbach Test Albritton & Herbert LLP; Treccartin, Richard F.; Silva, Robin M.

NUMBER OF CLAIMS: 16  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)  
LINE COUNT: 1320

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention relates to magnetic resonance imaging agents comprising a paramagnetic metal ion bound to a complex wherein said complex comprises a chelator and a blocking moiety covalently attached to said chelator which binds in at least a first coordination site of said metal ion and which is capable of interacting with a target substance such that the exchange of water in at least said first coordination site is increased.  
IT 7440-54-2D, Gadolinium, chelate complexes contg. covalently-attached blocking moiety (as MRI contrast agents for detection of physiol. agents)  
RN 7440-54-2 USPATFULL  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

IT 60239-18-1, DOTA

L8 ANSWER 22 OF 40 CAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1997:672302 CAPLUS  
DOCUMENT NUMBER: 127:316334  
TITLE: Bioactivated diagnostic imaging contrast agents  
INVENTOR(S): Lauffer, Randall B.; McMurtry, Thomas J.; Dunham, Stephen O.; Scott, Daniel M.; Parmelee, David J.; Dumas, Stephane  
PATENT ASSIGNEE(S): Epix Medical, Inc., USA  
SOURCE: PCT Int. Appl., 80 pp.  
CODEN: F1XXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9736619	A2	19971009	WO 1997-US4804	19970325
WO 9736619	A3	19980129		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2247620	AA	19971009	CA 1997-2247620	19970325
AU 9725448	A1	19971022	AU 1997-25448	19970325
AU 726914	B2	20001123		
BR 9708470	A	19990413	BR 1997-8470	19970325
EP 907379	A2	19990414	EP 1997-916974	19970325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1215341	A	19990428	CN 1997-193542	19970325
JP 2000507577	T2	20000620	JP 1997-535373	19970325
NO 9804543	A	19981126	NO 1998-4543	19980329
PRIORITY APPLN. INFO.: US 1996-14448 P 19960401 WO 1997-US4804 W 19970325				


AB Improved diagnostic agents for magnetic resonance imaging (MRI) and optical imaging are provided. In particular, this invention relates to MRI and optical imaging agents that allow for the sensitive detection of a specific bioactivity within a tissue. These agents are prodrug contrast agents which are bioactivated in vivo in the presence of the specific bioactivity. This invention also relates to pharmaceutical compns. comprising these agents and to methods of using the agents and compns. comprising the agents.

09/405,046


L8 ANSWER 22 OF 40 CAPLUS COPYRIGHT 2001 ACS (Continued)  
IT 7440-54-2D, Gadolinium, complexes with chelating agents  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(contrast agent image-enhancing moiety; bioactivated diagnostic  
imaging contrast agents and prepn. thereof)  
RN 7440-54-2 CAPLUS  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

IT 60239-10-1, DOTA  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(contrast agent moiety; bioactivated diagnostic imaging contrast  
agents and prepn. thereof)  
RN 60239-10-1 CAPLUS  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA  
INDEX NAME)



L8 ANSWER 23 OF 40 CAPLUS COPYRIGHT 2001 ACS (Continued)  
proviso that Xbb can only be Pyr when n = 0; Xcc, Xdd = Met, Leu,  
Nle;; R2  
= OH, acetoxy, amino; and thereupon (ii) subjecting said being to  
external imaging, by radioactive scanning or by magnetic resonance  
imaging, to det. the targeted sites in the body. Also provided is a  
method for the therapeutic treatment of malignant tumors by  
administration  
of the above-defined peptide, labeled for this purpose. Further  
provided are a method for labeling of the peptide compds., a  
pharmaceutical compn. to be used for detection, a pharmaceutical  
compn. to  
be used for therapy, and a kit for prepn. a radiopharmaceutical compn.  
The ligands of the invention specifically recognize CCK-B receptors.  
The  
methodol. of the invention is useful for detection of tumors which are  
difficult to characterize, e.g. small-cell lung carcinoma and  
medullary  
thyroid carcinoma.  
IT 60239-10-1D, DOTA, peptide conjugates  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(labeled CCK-B receptor ligands for detection, localization, and  
treatment of tumors, and prepn. thereof)  
RN 60239-10-1 CAPLUS  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA  
INDEX NAME)



IT 7440-54-2, Gadolinium, biological studies  
RL: BPR (Biological process); THU (Therapeutic use); BIOL (Biological  
study); PROC (Process); USES (Uses)  
(peptide labeled with labeled CCK-B receptor ligands for  
detection, localization, and treatment of tumors, and prepn.  
thereof)  
RN 7440-54-2 CAPLUS  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

L8 ANSWER 23 OF 40 CAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1997:594650 CAPLUS  
DOCUMENT NUMBER: 127:259530  
TITLE: Use of labeled CCK-B receptor ligands for the  
detection, localization, and treatment of  
malignant human tumors  
INVENTOR(S): Reubi, Jean-Claude  
PATENT ASSIGNEE(S): Mallinckrodt Medical, Inc., USA; Reubi,  
Jean-Claude  
SOURCE: PCT Int. Appl., 61 pp.  
CODEN: PIXX02  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9731657	A2	19970904	WO 1997-US3056	19970225
WO 9731657	A3	19971023		
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				
PT, SE				
CA 2247430	AA	19970904	CA 1997-2247430	19970225
EP 885017	A2	19981223	EP 1997-908751	19970225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,				
PT,				
IE, FI				
JP 2000506141	T2	20000523	JP 1997-531108	19970225
PRIORITY APPLN. INFO.:			EP 1996-200498	19960227
			WO 1997-US3056	19970225

OTHER SOURCE(S): MARPAT 127:259530  
AB A method is provided for detecting and localizing malignant tumors and  
their metastases in tissues, which in healthy condition do not contain  
disturbing quantities of CCK-receptors, in the body of a human being,  
which comprises (i) administering a compn. comprising, in a quantity  
sufficient for external imaging, a labeled peptide derived from  
H-(Xaa)n-(Xbb)m-Tyr-Xcc-Gly-Trp-Xdd-Asp-Phe-R2, or an acid amide  
thereof,  
formed between a free amino group of an amino acid moiety and R1COOH,  
[R1  
= C1-3 alkanoyl, arylcarbonyl, aryl-(C1-3)alkanoyl group; or a lactam  
thereof, formed between a free amino group of an amino acid moiety  
and a  
free CO2H group of another amino acid moiety; or a conjugate thereof  
with  
avidin or biotin; (Xaa)n = 0-25 amino acid moieties selected from  
Ala,  
Leu, Asn, Dpr, Gln, Glu, Ser, Ile, Met, His, Asp, Lys, Gly, Thr, Pro,  
Pyr,  
Arg, Tyr, Trp, Val, Phe; m = 0, 1; Xbb = Asp, Dpr, Glu or Pyr, with  
the


L8 ANSWER 24 OF 40 USPATFULL  
ACCESSION NUMBER: 97:96997 USPATFULL  
TITLE: Linear oligomeric polychelant compounds  
INVENTOR(S): Love, David B., Wayne, PA, United States  
Dow, William C., Wayne, PA, United States  
Himmelsbach, Richard J., Wayne, PA, United States  
Watson, Alan D., Wayne, PA, United States  
Rocklage, Scott M., Wayne, PA, United States  
Salutar, Inc., Sunnyvale, CA, United States (U.S.  
corporation)  
NUMBER DATE  
PATENT INFORMATION: US 5679810 19971021  
APPLICATION INFO.: US 1995-480056 19950607 (8)  
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-069996,  
filed  
on 7 Jul 1993, now patented, Pat. No. US 5446146  
which  
is a division of Ser. No. US 1990-468107, filed on  
19  
Jan 1990, now patented, Pat. No. US 5281704  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Gupta, Yogendra N.  
LEGAL REPRESENTATIVE: Fish & Richardson PC  
NUMBER OF CLAIMS: 12  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1846  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Linear oligomer polychelant compounds and chelates formed therewith  
have  
alternating chelant and linker moieties bound together by amide or  
ester  
moieties. The compounds have between 3 and 100 chelant moieties, at  
least one of which complexes a paramagnetic metal ion. The  
polychelants  
and especially their paramagnetic metal polychelates are  
particularly  
suitable for diagnostic imaging.  
IT 7440-54-2DP, Gadolinium, linear oligomeric polychelant  
polyaminocarboxylate complexes  
(prepn. for diagnostic imaging)  
RN 7440-54-2 USPATFULL  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd


IT 60239-10-1, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic  
acid  
(prepn. of linear oligomeric polychelant polyaminocarboxylic acids  
and  
their paramagnetic metal chelates for diagnostic imaging)  
RN 60239-10-1 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA  
INDEX NAME)

09/405,046

L8 ANSWER 24 OF 40 USPATFULL (Continued)  
NAME)




IT 137076-50-7P 137076-51-8P  
(prepn. of linear oligomeric polychelant polyaminocarboxylic acids  
and their paramagnetic metal chelates for diagnostic imaging)  
RN 137076-50-7 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tetraethyl  
ester (9CI) (CA INDEX NAME)



RN 137076-51-8 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, triethyl  
ester, potassium salt (9CI) (CA INDEX NAME)


L8 ANSWER 24 OF 40 USPATFULL (Continued)



● K


IT 137076-40-5P 137097-99-5P 197728-80-6P  
197728-81-7P  
(prepn. of linear oligomeric polychelant polyaminocarboxylic acids  
and their paramagnetic metal chelates for diagnostic imaging)  
RN 137076-40-5 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[1,2-  
ethanediylbis(imino(2-oxo-2,1-ethanediyl))]bis-, hexaethyl ester  
(9CI) (CA INDEX NAME)

PAGE 1-A




L8 ANSWER 24 OF 40 USPATFULL (Continued)

PAGE 1-B




RN 137097-99-5 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[1,2-  
ethanediylbis(imino(2-oxo-2,1-ethanediyl))]bis- (9CI) (CA INDEX  
NAME)

PAGE 1-A




PAGE 1-B




RN 197728-80-6 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10''-  
[nitrilotris[2,1-ethanediylimino(2-oxo-2,1-ethanediyl)]]tris- (9CI)  
(CA INDEX NAME)

L8 ANSWER 24 OF 40 USPATFULL (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B




```

RN 197728-81-7 USPATFULL
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
10,10'-[[2-methyl-2-
[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-
yl]acetyl]amino]methyl]-1,3-propanediyl]bis[imino(2-oxo-2,1-
ethanediy)]]]bis- (9CI) (CA INDEX NAME)

```


PAGE 1-A



US ANSWER 25 OF 40 USPATFULL  
 97:88724 USPATFULL  
 TITLE: In vivo agents comprising cationic metal chelators  
 with  
 acidic saccharides and glycosaminoglycans  
 INVENTOR(S): Ranney, David F., Dallas, TX, United States  
 PATENT ASSIGNEE(S): Access Pharmaceuticals, Inc., Dallas, TX, United States  
 States  
 (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5672334	19970930
APPLICATION INFO.:	US 1993-160085	19931129 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-880660, filed on 8 May 1992, now abandoned Ser. No. Ser. No. US 1991-863595, filed on 9 Dec 1991, now patented,	
Pat.	No. US 5214661 And a continuation-in-part of Ser.	
No.	US 1991-642033, filed on 16 Jan 1991, now patented, Pat. No. US 5336762	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Hollinden, Gary E.	
LEGAL REPRESENTATIVE:	Arnold, White & Durkee	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	53 Drawing Figure(s); 53 Drawing Page(s)	
LINE COUNT:	2220	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	AB This application concerns novel agents comprising cationic or chemically basic metal chelators in association with hydrophilic carriers of anionic or chemically acidic saccharides, sulfatides and glycosaminoglycans. In certain embodiments, the agents comprise metals and metal ions. Covalent and non-covalent chemical and physical means are described for stabilizing the binding of the metal chelators to the carriers. Novel non-covalently bound compositions are described which give uniquely high payloads and ratio of metal chelator to carrier, ranging from a low of about 15% metal chelator by weight, to a characteristic range of 70% to 90% metal chelator by weight.	
Specific	embodiments are described comprising deferroxamine, ferrioxamine, iron-basic porphine, iron-triethylenetetraamine, gadolinium, DTPA-lysine, gadolinium DOTA-lysine and gadolinium with basic derivatives of porphyrins, porphines, expanded porphyrins, Texaphyrins and sapphyrins as the basic or cationic metal chelators, which are in turn, bound to acidic or anionic carriers, including one or more of acidic or anionic	

PAGE 1-B



L8 ANSWER 25 OF 40 USPATFULL (Continued)  
saccharides, and including sulfated sucrose, pentosan polysulfate, dermatan sulfate, oversulfated dermatan sulfate, chondroitin sulfate, oversulfated chondroitin sulfate, heparan sulfate, beef heparin, porcine heparin, non-anticoagulant heparins, and other native and modified acidic saccharides and glycosaminoglycans.

Also disclosed are methods of enhancing in vivo images arising from induced magnetic resonance signals, methods of enhancing in vivo images in conjunction with ultrasound or X-rays and methods of obtaining in vivo body images utilizing radioisotope containing agents. Methods of treating vascular disease are also disclosed.

treating vascular disease are also disclosed.

IT 7440-54-2D, Gadolinium, chelates, conjugates with acidic saccharides and glycosaminoglycans 60239-18-1D, DOTA, basic or amine derivs., metal chelates, conjugates with acidic saccharides and glycosaminoglycans

(metal-ion chelates with acidic saccharides and glycosaminoglycans, agent prepn., and methods of enhancing MRI imaging)


RN 7440-54-2 USPATFULL  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

```

RN      60239-18-1  USPATFULL
CN      1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA
INDEX
      NAME)

```





09/405,046

L8 ANSWER 26 OF 40 USPATFULL  
 97:75803 USPATFULL  
 TITLE: Iodinated paramagnetic chelates, and their use as contrast agents  
 INVENTOR(S): Uggeri, Fulvio, Milan, Italy  
 Anelli, Pier Lucio, Milan, Italy  
 Fedeli, Franco, Milan, Italy  
 Murru, Marcella, Milan, Italy  
 De Haen, Christoph, Milan, Italy  
 Dibra S.p.A., Milan, Italy (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5660814	19970826
	WO 9427644	19941208
APPLICATION INFO.:	US 1995-448476	19950530 (8)
	WO 1994-EP1677	19940525
		19950530 PCT 371 date
		19950530 PCT 102(a) date

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1993-MI1155	19930602
	IT 1993-MI1274	19930615

DOCUMENT TYPE: Utility  
 PRIMARY EXAMINER: Knight, John  
 ASSISTANT EXAMINER: Jones, Dameron L.  
 LEGAL REPRESENTATIVE: Bucknam and Archer  
 NUMBER OF CLAIMS: 15  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 1420

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Novel compounds containing a polyiodinated aromatic or heteroaromatic residue and their chelate complexes with ions of metal elements with atomic number from 20 to 31, 39, from 42 to 44, 49 and from 57 to 83, and their salts with physiologically tolerable organic and inorganic bases are useful contrast agents for preparation of diagnostic formulations to obtain images of organs and/or tissues of human and animal body through the use of nuclear magnetic resonance or X-rays

or the combination of both nuclear magnetic resonance and X-rays.

IT 160982-30-9P  
 (prepn. of polyiodinated paramagnetic lanthanide chelates as NMR imaging contrast agents)

RN 160982-30-9 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,  
 10-[2-[(3-carboxy-2,4,6-triiodophenyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 26 OF 40 USPATFULL (Continued)




IT 7440-54-2P, Gadolinium, biological studies 160982-30-9DP  
 gadolinium complexes 160982-31-0DP, lanthanide complexes  
 160982-32-1DP, gadolinium complexes 160982-33-2DP,  
 gadolinium complexes 160982-34-3DP, gadolinium complexes  
 (prepn. of polyiodinated paramagnetic lanthanide chelates as NMR  
 imaging contrast agents)  
 RN 7440-54-2 USPATFULL  
 CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd


RN 160982-30-9 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,  
 10-[2-[(3-carboxy-2,4,6-triiodophenyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 26 OF 40 USPATFULL (Continued)




RN 160982-31-0 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(3-(2-carboxybutyl)-2,4,6-triiodophenyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 26 OF 40 USPATFULL (Continued)



PAGE 1-A



RN 160982-32-1 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,  
 10-[2-[[6-[(3-carboxy-2,4,6-triiodophenyl)amino]-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 160982-33-2 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[(3-(2-carboxybutyl)-2,4,6-triiodophenyl)amino]-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 2-A


09/405,046

L8 ANSWER 26 OF 40 USPATFULL (Continued)

PAGE 1-A




PAGE 2-A




RN 160982-34-3 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[(3,5-dicarboxy-2,4,6-triiodophenyl)amino]-6-oxohexyl]amino]-2-oxoethyl]-(9CI) (CA INDEX NAME)

L8 ANSWER 26 OF 40 USPATFULL (Continued)

PAGE 1-A



PAGE 2-A




L8 ANSWER 27 OF 40 USPATFULL

ACCESSION NUMBER: 97:3510 USPATFULL  
 TITLE: Medical compositions  
 INVENTOR(S): Bogdanov, Alexei A., Newton, MA, United States  
 Brady, Thomas J., Winchester, MA, United States  
 PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA,  
 United States (U.S. corporation)  
 NUMBER DATE  
 PATENT INFORMATION: US 5593658 19970114  
 APPLICATION INFO.: US 1994-250635 19940527 (8)  
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-940590, filed on  
 4 Sep 1992, now abandoned  
 DOCUMENT TYPE: Utility  
 PRIMARY EXAMINER: Hollinden, Gary E.  
 LEGAL REPRESENTATIVE: Fish & Richardson P.C.  
 NUMBER OF CLAIMS: 32  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 14 Drawing Figure(s); 9 Drawing Page(s)  
 LINE COUNT: 1331  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB A biocompatible medical composition including a polymeric carrier, a  
 group protective chain linked to the polymeric carrier, and a reporter  
 linked to the carrier or to the carrier and the protective chain.  
 The invention also relates to a method of treating a disease in a  
 patient by administering to the patient a therapeutically effective amount of  
 the composition, and may include scanning the patient using an imaging  
 technique which can detect the reporter group to obtain a visible  
 image of the distribution of the composition.  
 IT 7440-54-2D, Gadolinium, adducts with graft copolymer and platinum  
 compd. 60239-18-1D, 1,4,7,10-Tetraazacyclododecane-  
 N,N',N'',N'''-tetraacetic acid, adducts with graft copolymer and  
 platinum compd.  
 (graft copolymer-platinum compd. adduct prepn. and therapeutic use)  
 RN 7440-54-2 USPATFULL  
 CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

RN 60239-18-1 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA  
 INDEX NAME)

L8 ANSWER 27 OF 40 USPATFULL (Continued)



09/405,046

L8 ANSWER 28 OF 40 CAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1995:371854 CAPLUS  
DOCUMENT NUMBER: 125:29270  
TITLE: Diagnostic imaging contrast agent containing  
several  
detection groups per molecule  
INVENTOR(S): Ohtaka, Akiharu; Sugino, Hideki; Hashiguchi, Yuji;  
Seri, Shigemitsu; Iwai, Kumiko  
PATENT ASSIGNEE(S): Nihon Medi-Physics Co., Ltd., Japan  
SOURCE: Eur. Pat. Appl., 13 pp.  
CODEN: EPXKDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 709100	A1	19960501	EP 1995-114718	19950919
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
AU 9532834	A1	19960418	AU 1995-32834	19950922
AU 692590	B2	19980611		
JP 08151336	A2	19960611	JP 1995-273486	19950927
CA 2159530	AA	19960331	CA 1995-2159530	19950929
CA 2160052	AA	19970407	CA 1995-2160052	19951006
EP 766968	A1	19970409	EP 1995-115758	19951006
EP 766968	B1	20010117		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
AT 198713	E	20010215	AT 1995-115758	19951006
AU 9533189	A1	19970417	AU 1995-33189	19951011
AU 699499	B2	19981203		

PRIORITY APPLN. INFO.: JP 1994-261817 A 19940930  
EP 1995-115758 A 19951006


AB A diagnostic imaging agent is disclosed which comprises an oligomer metal complex compd. having mol. wt. of 1000-10,000 and having 2-10 functional groups reactive with a bifunctional ligand, wherein .gtoreq.1 kind of and .gtoreq.2 bifunctional ligands are coupled to the org. compd., the org. compd., after coupling to bifunctional ligands, having .gtoreq.1 hydroxyl group, and the org. compd. being coordinated with .gtoreq.1 kind of and .gtoreq.2 metal ions. Prepn. of e.g. OP1-DTPA-Gd is described (OP1 is synthetic peptide Pyr-Lys-Arg-Pro-Ser-Gln-Arg-Ser-Lys-Tyr-Leu). The oligomer metal complex compds. of the invention have remarkable relaxation time shortening effects.  
IT 7440-54-2D, Gadolinium, oligomer complexes 60239-18-1D, metal complexes, oligomer conjugates  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(diagnostic imaging contrast agent oligomer metal complex compds. with

L8 ANSWER 29 OF 40 USPATFULL  
ACCESSION NUMBER: 96:82819 USPATFULL  
TITLE: Adducts of macrocyclic chelants  
INVENTOR(S): Sieving, Paul F., San Jose, CA, United States  
Watson, Alan D., Campbell, CA, United States  
PATENT ASSIGNEE(S): Nycomed Salutar, Inc., Wayne, PA, United States  
(U.S. corporation)  
NUMBER DATE  
PATENT INFORMATION: US 5554748 19960910  
APPLICATION INFO.: US 1993-175989 19931230 (8)  
RELATED APPLN. INFO.: Division of Ser. No. US 1990-494865, filed on 16 Jan 1990, now patented, Pat. No. US 5364613 which is a continuation-in-part of Ser. No. US 1989-335162, filed on 7 Apr 1989, now abandoned  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Datlow, Philip I.  
LEGAL REPRESENTATIVE: Fish & Richardson P.C.  
NUMBER OF CLAIMS: 5  
EXEMPLARY CLAIMS: 1  
LINE COUNT: 1172  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB There are provided polychelants and their metal chelates which are useful in diagnostic imaging and in radiotherapy and which comprise a plurality of macrocyclic chelant moieties, e.g. DOTA residues, conjugated to a polyamine backbone molecule, e.g. polylysine. To produce a site-specific polychelate, one or more of the macrocyclic chelant carrying backbone molecules may be conjugated to a site-directed macromolecule, e.g. a protein. For example, adducts of a macrocyclic chelant can be formed by the process of (a) dispersing a carboxylic macrocyclic chelant in a polar, anhydrous solvent, (b) adding a base with a pKa sufficient to remove all carboxyl protons to create an amine salt of the chelant soluble in the solvent, (c) chilling the reaction mixture to between about 5.degree. C. and 55.degree. C. above the freezing point of the solvent, and (d) adding substantial equimolar amount of chilled alkylhaloformate under anhydrous conditions so as to form a slurry containing the mixture carboxycarbonic anhydride of the chelant.  
IT 134314-87-7D, reaction product with polylysine  
(polychelate, site-specific, for medicine)  
RN 134314-87-7 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, monoanhydride  
with (2-aminoethyl)carbamic acid (9CI) (CA INDEX NAME)


L8 ANSWER 28 OF 40 CAPLUS COPYRIGHT 2001 ACS (Continued)  
several detection groups per mol., and their prepn.)  
RN 7440-54-2 CAPLUS  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

RN 60239-18-1 CAPLUS  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)




L8 ANSWER 29 OF 40 USPATFULL (Continued)



IT 134314-84-4D, reaction product with polylysine  
(polychelate, site-specific, for radiotherapy and radioimaging)  
RN 134314-84-4 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, monoanhydride  
with [2-(4-aminophenyl)ethyl]carbamic acid (9CI) (CA INDEX NAME)


PAGE 1-A




09/405,046

L8 ANSWER 29 OF 40 USPATFULL (Continued)


PAGE 2-A



IT 134314-85-5P 134314-86-6P  
(prepn. and reaction of, with polylysine)  
RN 134314-85-5 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,  
monoanhydride  
with (2-isothiocyanatoethyl)carbamic acid (9CI) (CA INDEX NAME)




RN 134314-86-6 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,  
monoanhydride  
with [2-(bromoacetyl)amino]ethylcarbamic acid (9CI) (CA INDEX NAME)




L8 ANSWER 29 OF 40 USPATFULL (Continued)

L8 ANSWER 29 OF 40 USPATFULL (Continued)

IT 124098-81-3P  
(prepn. and reaction with amines)  
RN 124098-81-3 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,  
monoanhydride  
with 2-methylpropyl hydrogen carbonate (9CI) (CA INDEX NAME)



IT 60239-18-1, DOTA  
(reaction of, with iso-Bu chloroformate)  
RN 60239-18-1 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



IT 7440-54-2D, Gadolinium, complexes with DOTA deriv. polychelates  
(site-specific polychelate, for biomols., in radiotherapy and  
radioimaging)  
RN 7440-54-2 USPATFULL  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

L8 ANSWER 30 OF 40 USPATFULL

ACCESSION NUMBER: 96:36297 USPATFULL  
TITLE: Targeted polymerized liposome contrast agents  
INVENTOR(S): Li, King C., 21 Ryan Ct., Stanford, CA, United States  
States 94305  
Bednarski, Mark D., 816 Amber La., Los Altos, CA, United States 94024  
Storrs, Richard W., 2755 Rose Bud Ct., Union City, CA, United States 94587  
Li, Henry Y., 3350 W. Sunnyside Ave., Visalia, CA, United States 93277  
Trooper, Francois D., 1851 Magellan Dr., Oakland, CA, United States 94611  
Song, Curtis K. H., 548 E. Maude Ave., Sunnyvale, CA, United States 94086  
Sipkins, Dorothy A., 933 Addison St., Palo Alto, CA, United States 94301  
Kuniyoshi, Jeremy K., 22344 Carta Blanca St., Cupertino, CA, United States 95014

	NUMBER	DATE
PATENT INFORMATION:	US 5512294	19960430
APPLICATION INFO.:	US 1994-286555	19940805 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Kishore, Gollamudi S.	
LEGAL REPRESENTATIVE:	Speckman, Pauley & Fejer	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 19 Drawing Page(s)	
LINE COUNT:	881	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polymerized liposome particles based upon lipids having a functional group and a metal chelator to attach an imaging enhancement agent and lipids having an active targeting group to provide targeted polymerized liposome contrast agents. The polymerized imaging enhancement liposome particles interact with receptor targets holding the image enhancement agent to specific sites providing in vivo study by magnetic resonance, radioactive, x-ray or optical imaging of the expression of molecules in cells and tissues during disease and pathology.

IT 60239-18-1, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid  
(synthetic lipids prepd. from targeted polymd. liposome contrast agents)  
RN 60239-18-1 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

09/405,046

L8 ANSWER 30 OF 40 USPATFULL (Continued)  
NAME)



IT 7440-54-2 ZDP, Gadolinium, complexes with synthetic lipids  
(targeted polymd. liposome contrast agents)  
RN 7440-54-2 USPATFULL  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

L8 ANSWER 31 OF 40 USPATFULL  
ACCESSION NUMBER: 95:78284 USPATFULL  
TITLE: Polychelant compounds  
INVENTOR(S): Love, David B., Campbell, CA, United States  
Dow, William C., Fremont, CA, United States  
Himmelsbach, Richard J., Pleasanton, CA, United States  
States  
Watson, Alan D., Campbell, CA, United States  
Rocklage, Scott M., Los Gatos, CA, United States  
PATENT ASSIGNEE(S): Mycomed Salutar, Inc., Sunnyvale, CA, United States  
(U.S. corporation)


	NUMBER	DATE
PATENT INFORMATION:	US 5446145	19950829
APPLICATION INFO.:	US 1993-86996	19930707 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1990-468107, filed on 19 Jan	
DOCUMENT TYPE:	1718	
PRIMARY EXAMINER:	Utility	
ASSISTANT EXAMINER:	Shah, Mukund J.	
LEGAL REPRESENTATIVE:	Gupta, Y. N.	
NUMBER OF CLAIMS:	Lyon & Lyon	
EXEMPLARY CLAIM:	13	
LINE COUNT:	1	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB There are disclosed polychelant compounds, that is multi-site metal  
chelating agents, and chelates formed therewith. The polychelants  
and especially their paramagnetic metal, heavy metal or radioactive  
metal polychelates are particularly suitable for use in diagnostic  
imaging, heavy metal detoxification or radiotherapy. The polychelants have a  
linear or branched oligomeric structure comprising alternating  
chelant and linker moieties bound together by amide or ester moieties the  
carbonyl groups whereof being adjacent the chelant moieties, each  
polychelant comprising at least two said chelant moieties capable of  
complexing a metal ion.


IT 137076-40-5 137097-99-5  
(chelating agent, polychelant)  
RN 137076-40-5 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[1,2-  
ethanediylbis(imino(2-oxo-2,1-ethanediyl))]bis-, hexaethyl ester  
(9CI) (CA INDEX NAME)

L8 ANSWER 31 OF 40 USPATFULL (Continued)

PAGE 1-A




PAGE 1-B




RN 137097-99-5 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[1,2-  
ethanediylbis(imino(2-oxo-2,1-ethanediyl))]bis- (9CI) (CA INDEX  
NAME)

PAGE 1-A



L8 ANSWER 31 OF 40 USPATFULL (Continued)


PAGE 1-B



IT 7440-54-2, Gadolinium, reactions  
(complexation of, chelating agent for)  
RN 7440-54-2 USPATFULL  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd


IT 137076-50-7P 137076-51-8P 137076-54-1P  
(prepn. of, in polychelant chelating agent prepn.)  
RN 137076-50-7 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tetraethyl  
ester (9CI) (CA INDEX NAME)



RN 137076-51-8 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, triethyl  
ester, potassium salt (9CI) (CA INDEX NAME)


09/405,046

L8 ANSWER 31 OF 40 USPATFULL (Continued)




● X

RN 137076-54-1 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,  
tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 32 OF 40 USPATFULL (Continued)  
(9CI) (CA INDEX NAME)



● 2 K

IT 7440-54-2DP, Gadolinium, macrocycle complexes  
(prepn. of, for complex prep. for medical imaging agents)  
RN 7440-54-2 USPATFULL  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

L8 ANSWER 32 OF 40 USPATFULL

ACCESSION NUMBER: 95:45333 USPATFULL  
TITLE: Nitrogen-containing cyclic ligands, metallic  
complexes

INVENTOR(S):

formed by these ligands, diagnostic compositions  
containing these complexes and process for the  
preparation of the ligands  
Schaefer, Michel, Chilly-Mazarin, France  
Doucet, Didier, Livry-Gargan, France  
Bonnemain, Bruno, Villeparisis, France  
Meyer, Dominique, Paris, France  
Paris, Dominique, Aulnay-Sous-Bois, France  
Guerbet S.A., Villepinte, France (non-U.S.  
corporation)

PATENT ASSIGNEE(S):

NUMBER	DATE
PATENT INFORMATION:	US 5417960 19950523
APPLICATION INFO.:	US 1994-191461 19940203 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-730050, filed on 15 Jul 1991, now abandoned which is a division of US 1989-421592, filed on 16 Oct 1989, now patented, Fat. No. US 5049667 which is a continuation-in-part of Ser. No. US 1988-181056, filed on 13 Apr 1988, now abandoned

NUMBER	DATE
PRIORITY INFORMATION:	FR 1987-5288 19870414
	FR 1988-13585 19881014
DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Hollinden, Gary E.
LEGAL REPRESENTATIVE:	Jacobson, Price, Holman & Stern
NUMBER OF CLAIMS:	33
EXEMPLARY CLAIM:	1
LINE COUNT:	1170

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject of the invention is nitrogen-containing cyclic ligands  
and metal complexes formed by these ligands, the uses of these  
complexes as magnetic resonance imaging (MRI) agents, as X-ray contrast agents  
and as chemical shift reagents in vivo.

IT 119929-05-4P  
(prepn. and reaction of, in complex prep. for medical imaging  
agents)

RN 119929-05-4 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, dipotassium  
salt

L8 ANSWER 33 OF 40 USPATFULL

ACCESSION NUMBER: 95:33907 USPATFULL  
TITLE: Hybrid magnetic resonance contrast agents  
INVENTOR(S): Unger, Evan C., 13365 E. Camino La Cebadilla,  
Tucson,

AZ, United States 85749  
Wu, Guanli, 2601 W. Aiden St., Tucson, AZ, United  
States 85745

NUMBER	DATE
PATENT INFORMATION:	US 5407657 19950418
APPLICATION INFO.:	US 1994-202807 19940228 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-949691, filed on 22 Sep 1992


DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Acquah, Samuel A.  
LEGAL REPRESENTATIVE: Durando, Antonio R.; Weiss, Harry M.  
NUMBER OF CLAIMS: 87  
EXEMPLARY CLAIM: 1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel MRI contrast agents that comprise one or more metal-ion  
chelates in juxtaposition with one or more free-radical nitroxide compounds  
in a polymeric or oligomeric molecule. Both the chelate units and the  
free radical units may, independently, be inside the main chain of the  
polymer or in a side chain of the linkage portion of the polymer.  
The number of combined units of chelates and free radicals in the  
polymer or oligomer is at least two.

IT 60239-18-1, DOTA  
(polymeric mols. contg. chelate moieties and nitroxide moieties as  
hybrid MRI agents, and their prep.)

RN 60239-18-1 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA  
INDEX NAME)



IT 7440-54-2D, Gadolinium, complexes with hybrid polymers contg.  
chelating agents and nitroxides

09/405,046

L8 ANSWER 33 OF 40 USPATFULL (Continued)  
(polymeric mols. contg. chelate moieties and nitroxide moieties as  
hybrid MRI agents, and their prepn.)  
RN 7440-54-2 USPATFULL  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd


L8 ANSWER 34 OF 40 USPATFULL  
ACCESSION NUMBER: 95127057 USPATFULL  
TITLE: Biomodulators as universal imaging agents  
INVENTOR(S): Born, Jerry L., Albuquerque, NM, United States  
Eshima, Dennis, Albuquerque, NM, United States  
Mann, Paul L., Albuquerque, NM, United States  
Matwyoff, Nicholas A., Albuquerque, NM, United States  
States  
PATENT ASSIGNEE(S): University of New Mexico, Albuquerque, NM, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5401489	19950328
APPLICATION INFO.:	US 1991-694325	19910501 (7)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Stoll, Robert L.	
ASSISTANT EXAMINER:	Covert, John M.	
LEGAL REPRESENTATIVE:	Hillen, White, Zelano, & Branigan	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	1040	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Biomodulators, optionally linked to imaging-active moieties, can be administered to a host to enhance images thereof, e.g., NMR-, X-ray- or radio-images, preferably by increasing aberrant tissue signal intensity. Biomodulators can also condition tissue to enhance uptake of otherwise non-specific imaging agents. When linked to drugs, biomodulators can target the same to particular sites in the body.	
IT	7440-54-2D, Gadolinium, complexes with DTPA-galactose (tissue MRI enhancement with biomodulator and)	
RN	7440-54-2 USPATFULL	
CN	Gadolinium (8CI, 9CI) (CA INDEX NAME)	

Gd

IT 60239-18-1D, DOTA, saccharide conjugates, metal complexes (tissue imaging with, biomodulator enhancement of)  
RN 60239-18-1 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

L8 ANSWER 34 OF 40 USPATFULL (Continued)




L8 ANSWER 35 OF 40 USPATFULL  
ACCESSION NUMBER: 94:99669 USPATFULL  
TITLE: Polychelants containing macrocyclic chelant moieties  
INVENTOR(S): Sieving, Paul F., 3166 Impala Dr. #5, San Jose, CA, United States 95117  
Watson, Alan D., 262A Rincon Ave., Campbell, CA, United States 95008  
Quay, Steven C., 428 Oakmead Pkwy., Sunnyvale, CA, United States 94086  
Rocklage, Scott M., 255 Cresci Rd., Los Gatos, CA, United States 95030


	NUMBER	DATE
PATENT INFORMATION:	US 5364613	19941115
APPLICATION INFO.:	US 1990-464865	19900116 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1989-335162, filed on 7 Apr 1989, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Michl, Paul R.	
ASSISTANT EXAMINER:	Yoon, Tae H.	
LEGAL REPRESENTATIVE:	Lyon & Lyon	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1352	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	There are provided polychelants and their metal chelates which are useful in diagnostic imaging and in radiotherapy and which comprise a plurality of macrocyclic chelant moieties, e.g. DOTA residues, conjugated to a polyamine backbone molecule, e.g. polylysine. To produce a site-specific polychelate, one or more of the macrocyclic chelant carrying backbone molecules may be conjugated to a site-directed macromolecule, e.g. a protein.	
IT	60239-18-1D, DOTA, reaction products with amine group-contg. backbone 150467-20-2D, reaction products with amine group-contg. backbone 160363-61-1D, reaction products with amine group-contg. backbone (polychelants contg. macrocyclic chelant moieties for use in radiotherapy and diagnostic imaging)	
RN	60239-18-1 USPATFULL	
CN	1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)	

09/405,046

L8 ANSWER 35 OF 40 USPATFULL (Continued)




RN 150467-20-2 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-aminoethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 160363-61-1 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-(2-aminophenyl)ethyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 35 OF 40 USPATFULL (Continued)



L8 ANSWER 35 OF 40 USPATFULL (Continued)



IT 7440-54-2DP, Gadolinium, complexes with polylysine-polyDOTA  
160363-62-2P  
(polychelants contg. macrocyclic chelant moieties for use in radiotherapy and diagnostic imaging, and their prepn.)  
RN 7440-54-2 USPATFULL  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

RN 160363-62-2 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, monoanhydride with carbonic acid (9CI) (CA INDEX NAME)


L8 ANSWER 36 OF 40 USPATFULL

ACCESSION NUMBER: 94:68850 USPATFULL  
TITLE: Polychelating agents for image and spectral enhancement (and spectral shift)  
INVENTOR(S): Ranney, David F., Dallas, TX, United States  
PATENT ASSIGNEE(S): Access Pharmaceuticals, Inc., Dallas, TX, United States (U.S. corporation)  
NUMBER DATE  
-----  
PATENT INFORMATION: US 5336762 19940809  
APPLICATION INFO.: US 1991-642033 19910116 (7)  
DISCLAIMER DATE: 20091013  
RELATED APPLN. INFO.: Division of Ser. No. US 1987-86692, filed on 7 Aug 1987, now abandoned which is a continuation-in-part of Ser. No. US 1985-799757, filed on 18 Nov 1985, now abandoned  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Lovering, Richard D.  
ASSISTANT EXAMINER: Covert, John M.  
LEGAL REPRESENTATIVE: Arnold, White & Durkee  
NUMBER OF CLAIMS: 28  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2147  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention includes an image-enhancing agent comprising a biodegradable, water-soluble polymer, synthetic or naturally derived and having repeating hydrophilic monomeric units with amino or hydroxyl groups. This agent also includes chelating agents comprising functional groups bound to an amino or hydroxyl group of the monomeric units. These chelating agents have a formation constant for divalent or trivalent metal cations of at least about 10<sup>sup.8</sup> at physiological temperature and pH. This image-enhancing agent is biodegradable to intermediary metabolites, excretable chelates, oligomers, monomers or combinations thereof of low toxicity. These image-enhancing agents may further comprise a paramagnetic metal ion for enhancement of the image arising from induced magnetic resonance signals. Images resulting from scanning of gamma particle emissions may be enhanced when the image-enhancing agent of the present invention comprises radioisotopic metal ions emitting gamma particles. The physical conversion of these image-enhancing agents into microspheres (or, less optimally, microaggregates) allows further internal directioning of the image-enhancing agents to organs with phagocytic capabilities. Dextran is a preferred polymer; DTPA and gadolinium are respectively preferred chelating agents and paramagnetic metal ions.



09/405,046

L8 ANSWER 36 OF 40 USPATFULL (Continued)  
 IT 7440-54-2D, Gadolinium, complexes with polymer-chelating agents  
 60239-18-1D, conjugates with polymers and metal ions  
 (as image-enhancement agents)  
 RN 7440-54-2 USPATFULL  
 CN Gadolinium (8CI, 9CI) (CA INDEX NAME)  
 Gd  
 RN 60239-18-1 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA  
 INDEX NAME)



L8 ANSWER 37 OF 40 USPATFULL  
 ACCESSION NUMBER: 94:7797 USPATFULL  
 TITLE: Polychelant compounds  
 INVENTOR(S): Love, David B., Campbell, CA, United States  
 Dow, William C., Fremont, CA, United States  
 Himmelsbach, Richard J., Pleasanton, CA, United States  
 States  
 Watson, Alan D., Campbell, CA, United States  
 Rocklage, Scott M., Los Gatos, CA, United States  
 PATENT ASSIGNEE(S): Salutar, Inc., Sunnyvale, CA, United States (U.S. corporation)


	NUMBER	DATE
PATENT INFORMATION:	US 5281704	19940125
APPLICATION INFO.:	US 1990-468107	19900119 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1989-23843	19891023
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Ward, E. C.	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1759	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB There are disclosed polychelant compounds, that is multi-site metal chelating agents, and chelates formed therewith. The polychelants and especially their paramagnetic metal, heavy metal or radioactive metal polychelates are particularly suitable for use in diagnostic imaging, heavy metal detoxification or radiotherapy. The polychelants have a linear or branched oligomeric structure comprising alternating chelant and linker moieties bound together by amide or ester moieties the carbonyl groups whereof being adjacent the chelant moieties, each polychelant comprising at least two said chelant moieties capable of complexing a metal ion.  
 IT 137076-40-5 137097-99-5 (chelating agent, polychelant)  
 RN 137076-40-5 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[1,2-ethanediylbis(imino(2-oxo-2,1-ethanediyl))]bis-, hexaethyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 37 OF 40 USPATFULL (Continued)

PAGE 1-A




PAGE 1-B




RN 137097-99-5 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[1,2-ethanediylbis(imino(2-oxo-2,1-ethanediyl))]bis- (9CI) (CA INDEX NAME)

PAGE 1-A



L8 ANSWER 37 OF 40 USPATFULL (Continued)


PAGE 1-B



IT 7440-54-2, Gadolinium, reactions  
 (complexation of, chelating agent for)  
 RN 7440-54-2 USPATFULL  
 CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd


IT 137076-50-7P 137076-51-8P 137076-54-1P  
 (prepn. of, in polychelant chelating agent prepn.)  
 RN 137076-50-7 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tetraethyl ester (9CI) (CA INDEX NAME)



RN 137076-51-8 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, triethyl ester, potassium salt (9CI) (CA INDEX NAME)


09/405,046

L8 ANSWER 37 OF 40 USPATFULL (Continued)



● K

RN 137076-54-1 USPATFULL  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,  
tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 38 OF 40 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1993:620702 CAPLUS  
DOCUMENT NUMBER: 119:220702  
TITLE: Dendrimeric polychelants as imaging agents  
INVENTOR(S): Watson, Alan D.  
PATENT ASSIGNEE(S): Cockbain, Julian Roderick Michaelson, UK; Nycomed Salutar, Inc.  
SOURCE: PCT Int. Appl., 57 pp.  
CODEN: PIXXD2  
Patent  
DOCUMENT TYPE: English  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9306868	A1	19930415	WO 1992-EP2308	19921006
W:	AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW,			
NO,	PL, RO, RU, SD, US			
BF,	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE,			
	BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG			
AU 9226757	A1	19930503	AU 1992-26757	19921006
AU 671601	B2	19960905		
EP 607222	A1	19940727	EP 1992-920822	19921006
EP 607222	B1	19981223		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE			
JP 07503031	T2	19950330	JP 1992-506624	19921006
AT 174800	E	19990115	AT 1992-920822	19921006
PRIORITY APPLN. INFO.:			US 1991-772349	19911007
			WO 1992-EP2308	19921006
AB	Polyvalent chelating agents, comprising multiple macrocyclic chelating moieties conjugated to a .ltoreq.5th-generation dendrimer backbone, and their metal chelates are useful in diagnostic imaging and radiotherapy.			
	To produce a site-specific agent, .gtoreq.1 of the chelating agent-carrying backbone mols. may be conjugated to a site-directed mol., e.g. a protein. Thus, Me acrylate reacted with NH3-MeOH to form N(CH2CH2CO2Me)3, which combined with H2NCH2CH2NH2 to form a 1st-generation starburst dendrimer; further generations were produced by alternate reaction of the product with Me acrylate and H2NCH2CH2NH2.			
A	2nd-generation dendrimer was coupled to 12 equiv. of DOTA carboxycarbonic anhydride, complexed with Gd, and conjugated via succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate to 2-aminothioliene-activated antibody L6.			
IT	7440-54-2D, Gadolinium, starburst dendritic polymer-macrocylic			


L8 ANSWER 38 OF 40 CAPLUS COPYRIGHT 2001 ACS (Continued)  
chelates 60239-18-1D, conjugates with starburst dendritic polymers, metal complexes 150467-20-2D, conjugates with starburst dendritic polymers, metal complexes 151790-71-5D, conjugates with starburst dendritic polymers, metal complexes RL: BIOL (Biological study)

(for diagnostic imaging and radiotherapy)


RN 7440-54-2 CAPLUS  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

RN 60239-18-1 CAPLUS  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)




RN 150467-20-2 CAPLUS  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-aminoethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 151790-71-5 CAPLUS  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-(4-aminophenyl)ethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 38 OF 40 CAPLUS COPYRIGHT 2001 ACS (Continued)


PAGE 1-A



PAGE 2-A

IT 60239-18-1, DOTA  
RL: RCT (Reactant)  
(reaction of, with iso-Bu chloroformate)

RN 60239-18-1 CAPLUS  
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



09/405,046

L8 ANSWER 38 OF 40 CAPLUS COPYRIGHT 2001 ACS (Continued)

L8 ANSWER 39 OF 40 USPATFULL  
 ACCESSION NUMBER: 92:84972 USPATFULL  
 TITLE: Polychelating agents for image and spectral enhancement  
 (and spectral shift)  
 INVENTOR(S): Ranney, David F., Dallas, TX, United States  
 PATENT ASSIGNEE(S): Access Pharmaceuticals Inc., Dallas, TX, United States  
 (U.S. corporation)


	NUMBER	DATE
PATENT INFORMATION:	US 5155215	19921013
APPLICATION INFO.:	US 1990-613465	19901107 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1985-799757, filed on 18 Nov 1985, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Maples, John S.	
LEGAL REPRESENTATIVE:	Arnold, White & Durkee	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1589	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB The present invention includes an image-enhancing agent comprising a biodegradable, water-soluble polymer, synthetic or naturally derived and having repeating hydrophilic monomeric units with amino or hydroxyl groups. This agent also includes chelating agents comprising functional groups bound to an amino or hydroxyl group of the monomeric units. These chelating agents have a formation constant for divalent or trivalent metal cations of at least about 10.sup.8 at physiological temperature and pH. This image-enhancing agent is biodegradable to intermediary metabolites, excretable chelates, oligomers, monomers or combinations thereof of low toxicity.		
These image-enhancing agents may further comprise a paramagnetic metal ion for enhancement of the image arising from induced magnetic resonance signals.		
Images resulting from scanning of gamma particle emissions may be enhanced when the image-enhancing agent of the present invention comprise radioisotopic metal ions emitting gamma particles.		
The physical conversion of these image enhancing agents into microspheres allows further internal directioning of the image-enhancing		

L8 ANSWER 39 OF 40 USPATFULL (Continued)  
 agents to organs with phagocytic capabilities.

Dextran is a preferred polymer DTPA and gadolinium are respectively preferred chelating agents and paramagnetic metal ions.  
 IT 7440-54-2D, Gadolinium, complexes with polymer-chelating agents  
 60239-18-1D, conjugates with polymers and metal ions  
 (as image-enhancement agents)  
 RN 7440-54-2 USPATFULL  
 CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd

RN 60239-18-1 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L8 ANSWER 40 OF 40 USPATFULL  
 ACCESSION NUMBER: 91:75813 USPATFULL  
 TITLE: Nitrogen-containing cyclic ligands  
 INVENTOR(S): Schaefer, Michel, Chilly-Mazarin, France  
 Doucet, Didier, Livry-Gargan, France  
 Bonnemain, Bruno, Villeparisis, France  
 Meyer, Dominique, Paris, France  
 Paris, Dominique, Aulnay-Sous-Bois, France  
 Guerbet S.A., Villepinte, France (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5049667	19910917
APPLICATION INFO.:	US 1989-421592	19891016 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1988-181056, filed on 13 Apr 1988, now abandoned	


	NUMBER	DATE
PRIORITY INFORMATION:	FR 1987-5288	19870414
	FR 1988-13585	19881014
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Springer, David B.	
LEGAL REPRESENTATIVE:	Wegner, Cantor, Mueller & Player	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1159	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The subject of the invention is nitrogen-containing cyclic ligands and metal complexes formed by these ligands, the uses of these complexes as magnetic resonance imaging (MRI) agents, as X-ray contrast agents and as chemical shift reagents in vivo.

IT 119929-05-4P  
 (prepn. and reaction of, in complex prepn. for medical imaging agents)  
 RN 119929-05-4 USPATFULL  
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, dipotassium salt  
 (9CI) (CA INDEX NAME)

09/405,046

L8 ANSWER 40 OF 40 USPATFULL (Continued)



● 2 K

IT 7440-54-ZDP, Gadolinium, macrocycle complexes  
(prepn. of, for complex prepn. for medical imaging agents)  
RN 7440-54-2 USPATFULL  
CN Gadolinium (8CI, 9CI) (CA INDEX NAME)

Gd